WO2023054006A1 - Opioid receptor antagonist and pharmaceutical composition - Google Patents
Opioid receptor antagonist and pharmaceutical composition Download PDFInfo
- Publication number
- WO2023054006A1 WO2023054006A1 PCT/JP2022/034681 JP2022034681W WO2023054006A1 WO 2023054006 A1 WO2023054006 A1 WO 2023054006A1 JP 2022034681 W JP2022034681 W JP 2022034681W WO 2023054006 A1 WO2023054006 A1 WO 2023054006A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- opioid receptor
- formula
- opioid
- Prior art date
Links
- 229940123257 Opioid receptor antagonist Drugs 0.000 title claims abstract description 28
- 239000003401 opiate antagonist Substances 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 21
- 102000003840 Opioid Receptors Human genes 0.000 claims abstract description 20
- 108090000137 Opioid Receptors Proteins 0.000 claims abstract description 20
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 19
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 239000011734 sodium Substances 0.000 claims description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 29
- 229960004127 naloxone Drugs 0.000 description 29
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- -1 bicyclo[2.2.1]heptyl Chemical group 0.000 description 23
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 19
- 229960002428 fentanyl Drugs 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 229960005181 morphine Drugs 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 231100000673 dose–response relationship Toxicity 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 230000008485 antagonism Effects 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229940124636 opioid drug Drugs 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940118548 Opioid mu receptor agonist Drugs 0.000 description 2
- 229940100208 Opioid mu receptor antagonist Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003269 fluorescent indicator Substances 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- YDJXNYNKKXZBMP-UHFFFAOYSA-N n-phenethyl-4-piperidinone Chemical compound C1CC(=O)CCN1CCC1=CC=CC=C1 YDJXNYNKKXZBMP-UHFFFAOYSA-N 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- AXQACEQYCPKDMV-RZAWKFBISA-N (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-n-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3C(O)=C(C[C@]2(O)[C@]34CC1)C(=O)NC(C)(C)C=1ON=C(N=1)C=1C=CC=CC=1)CC1CC1 AXQACEQYCPKDMV-RZAWKFBISA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- RPABADYMEMUBEC-UHFFFAOYSA-N 1-oxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC11OCCC1 RPABADYMEMUBEC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JJVKJJNCIILLRP-UHFFFAOYSA-N 2-ethyl-6-methylaniline Chemical compound CCC1=CC=CC(C)=C1N JJVKJJNCIILLRP-UHFFFAOYSA-N 0.000 description 1
- DDTKYVBFPULMGN-UHFFFAOYSA-N 2-methyl-6-propan-2-ylaniline Chemical compound CC(C)C1=CC=CC(C)=C1N DDTKYVBFPULMGN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 125000004062 acenaphthenyl group Chemical group C1(CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000005382 boronyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate group Chemical group [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229950002907 naldemedine Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M thiocyanate group Chemical group [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to novel opioid receptor antagonists and pharmaceutical compositions.
- Fentanyl is a synthetic opioid ⁇ receptor agonist represented by the following formula, and is used as a narcotic analgesic to treat cancer pain. While fentanyl has a strong analgesic effect, it has a narrow safety margin and is prone to side effects.
- naloxone, naltrexone, naldemedine, etc. which are opioid receptor antagonists, are known as therapeutic agents for side effects and addictive symptoms caused by opioid drugs.
- opioid receptor antagonists have also been proposed (see, for example, Patent Document 1).
- An object of the present invention is to provide a novel opioid receptor antagonist and pharmaceutical composition.
- ⁇ 1> Containing as an active ingredient one atropisomer having an opioid receptor antagonistic action or a pharmacologically acceptable salt thereof among a pair of atropisomers possessed by the compound represented by the following formula (1) opioid receptor antagonists.
- R 1 represents an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a non-aromatic heterocyclic group, or a heteroaryl group, and may have a substituent.
- Each R4 independently represents a hydrogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a non-aromatic heterocyclic group, or a heteroaryl group.
- R 1 in formula (1) is a heteroaryl group
- R 2 and R 3 are each independently an alkyl group.
- ⁇ 3> The opioid receptor antagonist according to ⁇ 1> or ⁇ 2>, which exhibits an antagonistic effect on opioid ⁇ receptors.
- ⁇ 4> Contains, as the active ingredient, an atropisomer represented by the following formula (2) and having a positive specific rotation at 20°C with respect to the sodium D line when dissolved in chloroform, ⁇ 1> ⁇
- ⁇ 5> Contains, as the active ingredient, an atropisomer represented by the following formula (3) and having a positive specific rotation at 20°C with respect to the sodium D line when dissolved in methanol, ⁇ 1> ⁇
- ⁇ 6> Contains, as an active ingredient, one atropisomer having an opioid receptor antagonistic action or a pharmacologically acceptable salt thereof, out of the pair of atropisomers possessed by the compound represented by the following formula (1)
- R 1 represents an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a non-aromatic heterocyclic group, or a heteroaryl group, and may have a substituent.
- Each R4 independently represents a hydrogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a non-aromatic heterocyclic group, or a heteroaryl group.
- novel opioid receptor antagonists and pharmaceutical compositions can be provided.
- FIG. 4 shows dose-response curves when compound 3F (3F), compound 3L (3L), or fentanyl (FN) was added to opioid ⁇ receptor-expressing cells (CHO- ⁇ cells).
- FIG. 4 shows dose-response curves of pretreatment of opioid ⁇ receptor-expressing cells (CHO- ⁇ cells) with compound 3F (3F) or naloxone (NLX) followed by addition of fentanyl.
- FIG. 10 is a graph showing changes over time in the amount of locomotion every 10 minutes after administration of morphine (Mor) after administration of compound 3F (3F), naloxone (NLX), and saline (SAL) to mice. .
- FIG. 1 shows dose-response curves when compound 3F (3F), compound 3L (3L), or fentanyl (FN) was added to opioid ⁇ receptor-expressing cells (CHO- ⁇ cells).
- FIG. 4 shows dose-response curves of pretreatment of opioid ⁇ receptor-expressing cells
- FIG. 10 shows total locomotion for 120 minutes after administration of morphine when mice were administered compound 3F (3F), naloxone (NLX), saline (SAL), and then morphine (Mor).
- FIG. 4 shows dose-response curves when compound 5F (5F) or compound 5L (5L) was added to opioid ⁇ receptor-expressing cells (CHO- ⁇ cells).
- FIG. 4 shows dose-response curves of pretreatment of opioid ⁇ receptor-expressing cells (CHO- ⁇ cells) with compound 5F (5F) or naloxone (NLX) followed by addition of fentanyl.
- the opioid receptor antagonist according to the present embodiment is one atropisomer having opioid receptor antagonistic activity among a pair of atropisomers possessed by the compound represented by the following formula (1) (hereinafter referred to as "specific atropisomer isomer”) or a pharmacologically acceptable salt thereof as an active ingredient.
- “Atropisomer” refers to structural isomers based on axial or planar chirality.
- the compound represented by the above formula (1) is a bond between the carbon atom at position 1 in the benzene ring having R 2 and R 3 at positions 2 and 6 and the nitrogen atom at position 4 of the piperidine ring. It has a pair of atropisomers (Ra form and Sa form) derived from axial asymmetry due to restricted rotation of (carbon-nitrogen bond) due to steric hindrance.
- the opioid receptor antagonist according to this embodiment contains one atropisomer having opioid receptor antagonistic activity or a pharmacologically acceptable salt thereof as an active ingredient.
- the opioid receptor antagonist according to the present embodiment contains any atropisomer. good too.
- R 1 represents an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a non-aromatic heterocyclic group, or a heteroaryl group, and may have a substituent.
- Each R4 independently represents a hydrogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a non-aromatic heterocyclic group, or a heteroaryl group.
- the alkyl group preferably has 1 to 20 carbon atoms such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, sec-butyl group, isobutyl group, tert-butyl group, pentyl group, isopentyl group and hexyl group.
- Cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl and tricyclo[2.2.1.0 ] groups having 3 to 20 carbon atoms, preferably 3 to 10 carbon atoms, such as heptyl groups.
- the alkenyl group includes a vinyl group, allyl group, propenyl group, isopropenyl group, butenyl group, isobutenyl group, 1,3-butadienyl group, pentenyl group, hexenyl group, etc., having 2 to 20 carbon atoms, preferably 2 to 2 carbon atoms. Ten linear or branched groups are included.
- the alkynyl group includes linear or branched groups having 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms, such as ethynyl group, propynyl group, butynyl group, pentynyl group and hexynyl group.
- Aryl groups include monocyclic or 2- to 4-ring condensed polycyclic groups such as phenyl group, naphthyl group, anthryl group, phenanthryl group, pyrenyl group, fluorenyl group, indenyl group, acenaphthylenyl group, indanyl group and acenaphthenyl group. is mentioned.
- Non-aromatic heterocyclic groups include azetidinyl, pyrrolidinyl, pyrrolinyl, piperidyl, tetrahydropyridyl, homopiperidinyl, octahydroazocinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, and homopiperazinyl.
- monocyclic nitrogen-containing groups such as groups, 2-piperazinonyl groups; monocyclic oxygen-containing groups such as tetrahydrofuranyl groups, tetrahydropyranyl groups and pyranyl groups; monocyclic nitrogen-containing/oxygen groups such as morpholinyl groups monocyclic nitrogen-sulfur groups such as a thiomorpholinyl group; Bicyclic oxygen-containing groups such as isochromanyl group, 1,3-benzodioxolyl group, 1,3-benzodioxanyl group, 1,4-benzodioxanyl group; 2,3-dihydrobenzothienyl group bicyclic sulfur-containing groups such as; [3.3]octyl group, 2-oxaspiro[3.3]octyl group, 6-aza-2-oxaspiro[3.3]octyl group, 1-azaspiro[4.5]decyl group, 1-oxaspiro[4 .5] a
- Heteroaryl groups include monocyclic nitrogen-containing groups such as pyrrolyl, pyridyl, imidazolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazolyl, and tetrazolyl; monocyclic nitrogen-containing groups such as furanyl; Oxygen-containing groups; monocyclic sulfur-containing groups such as thienyl; monocyclic nitrogen-containing and oxygen groups such as oxazolyl, isoxazolyl and oxadiazolyl groups; monocyclic groups such as thiazolyl, isothiazolyl and thiadiazolyl nitrogen/sulfur groups; Bicyclic nitrogen-containing groups such as a quinazolinyl group, quinoxalinyl group, naphthyridinyl group, pyrrolopyridyl group, imidazopyridyl group, pyrazolopyridyl group, pyridopyr
- the halogen atom includes a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, and the like.
- R 1 to R 3 may have include an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a non-aromatic heterocyclic group, a heteroaryl group, a cyano group, a halogen atom, hydroxy group, amino group, nitro group, nitroxy group, mercapto group, cyanate group, thiocyanate group, isothiocyanate group, sulfo group, sulfamino group, sulfino group, sulfamoyl group, phospho group, phosphono group, boronyl group and the like.
- the compound represented by formula (1) above has an acidic functional group or a basic functional group
- the compound may be in the form of a salt.
- the compound may be an alkali metal salt (sodium salt, potassium salt, etc.), an alkaline earth metal salt (calcium salt, magnesium salt, etc.), It may be in the form of an ammonium salt or the like.
- the compound represented by the above formula (1) when the compound represented by the above formula (1) has a basic functional group, the compound may be in the form of a salt with an inorganic acid such as hydrochloric acid or phosphoric acid, acetic acid, fumaric acid, methane It may be in the form of a salt with an organic acid such as sulfonic acid.
- an inorganic acid such as hydrochloric acid or phosphoric acid, acetic acid, fumaric acid, methane
- an organic acid such as sulfonic acid.
- the specific atropisomer or a salt thereof which is the active ingredient of the opioid receptor antagonist according to the present embodiment, may exhibit an antagonistic effect on any type of opioid receptor, but at least on the opioid ⁇ receptor. It is preferable to show an antagonistic action against The antagonistic action of a specific atropisomer or a salt thereof on the opioid ⁇ receptor can be confirmed, for example, by measuring the 50% inhibitory concentration ( IC50 value) according to the method described in Test Example 1 below.
- An example of a particularly preferred compound among the specific atropisomers is represented by the following formula (2) and has a positive specific rotation at 20° C. with respect to the sodium D line (wavelength 589 nm) when dissolved in chloroform.
- a compound showing In formula (2) -Me represents a methyl group, and -Et represents an ethyl group. This compound exhibits a stronger opioid ⁇ receptor antagonistic activity than naloxone, as shown in Test Example 1 described later.
- a particularly preferred compound among the specific atropisomers is represented by the following formula (3), and specific rotation at 20° C. with respect to the sodium D line (wavelength 589 nm) when dissolved in methanol is a positive value.
- formula (3) -Me represents a methyl group. As shown in Test Example 3 described later, this compound exhibits a strong opioid ⁇ receptor antagonistic activity, though weaker than that of naloxone.
- a specific atropisomer or a salt thereof, which is the active ingredient of the opioid receptor antagonist according to the present embodiment, can be obtained, for example, by optically resolving the racemate by chiral column chromatography or the like.
- the opioid receptor antagonist according to the present embodiment of the pair of atropisomers possessed by the compound represented by the above formula (1), is different from the specific atropisomer, as long as it exhibits opioid receptor antagonistic activity. It may contain atropisomers or salts thereof. In this case, the enantiomeric excess of the specific atropisomer or salt thereof may be 0% ee or more, 20% ee or more, 40% ee or more, or 60% ee. 80% ee or more, 90% ee or more, or 95% ee or more.
- the opioid receptor antagonist according to the present embodiment can contain ingredients other than the active ingredient, depending on the mode of use.
- the opioid receptor antagonist according to this embodiment can contain a pharmacologically acceptable carrier.
- the opioid receptor antagonist according to this embodiment may be used for medical purposes, or may be used for purposes other than medicine (research purposes, etc.).
- the opioid receptor antagonist according to this embodiment is used for medical purposes, the dosage form, indications, etc. may be the same as those of the pharmaceutical composition described later.
- the pharmaceutical composition according to this embodiment contains the above-described specific atropisomer or a pharmacologically acceptable salt thereof as an active ingredient.
- the specific atropisomer or its salt, which is the active ingredient, has opioid receptor antagonistic activity. Therefore, the pharmaceutical composition according to this embodiment can be applied to symptoms requiring opioid receptor antagonism.
- the pharmaceutical composition according to the present embodiment is used to improve or treat side effects of opioid drugs (constipation, nausea, vomiting, pruritus, hypotension, respiratory depression, delayed awakening, etc.) and toxic symptoms (respiratory depression, etc.). can be used for
- the pharmaceutical composition according to this embodiment can also be used as a treatment adjuvant for alcoholism.
- the pharmaceutical composition according to this embodiment preferably contains a pharmacologically acceptable carrier in addition to the active ingredient.
- Pharmaceutically acceptable carriers include organic or inorganic carriers commonly used as pharmaceutical materials. This carrier is used as an excipient, lubricant, binder, disintegrant, etc. in solid formulations, and as a solvent, solubilizer, suspending agent, tonicity agent, buffer, etc. in liquid formulations. blended.
- the pharmaceutical composition according to this embodiment may contain formulation additives such as preservatives, antioxidants and coloring agents.
- the dosage form of the pharmaceutical composition according to this embodiment is not particularly limited. Dosage forms of the pharmaceutical composition include oral agents such as tablets, capsules, emulsions and suspensions; parenteral agents such as injections, drops, nasal drops and external preparations; and the like.
- the dosage of the pharmaceutical composition according to this embodiment is appropriately determined according to the administration subject, administration route, symptoms, and the like.
- Step 3 Optical resolution of compound 3 Since compound 3 is racemic, each atropisomer was separated and isolated by chiral high performance liquid chromatography (HPLC).
- the atropisomer with a faster elution time is designated as compound 3F
- the atropisomer with a later elution time is designated as compound 3L.
- the enantiomeric excess of compound 3F was 97.9% ee
- the enantiomeric excess of compound 3L was 96.9% ee.
- the activation free energy value ⁇ G ⁇ between compound 3F and compound 3L was 126.7 kJ/mol (80° C., toluene).
- [ ⁇ ] D 20 (3 L): ⁇ 4.43° (c 0.15, CHCl 3 )
- ⁇ Test Example 1 Evaluation of in vitro opioid ⁇ receptor activity and opioid ⁇ receptor antagonistic activity of compound 3F and compound 3L>
- Opioid ⁇ receptor-expressing cells (CHO- ⁇ cells) were suspended in a nutritive mixture/Ham's F-12 medium containing 10% FBS, and seeded in a 96-well plate at 5.0 ⁇ 10 4 cells/well. , 37° C., 5.0% CO 2 . After 24 hours, the medium was replaced with 100 ⁇ L/well of Component B (HBSS + 20 mM HEPES buffer, pH 7.4), and a calcium-sensitive fluorescent indicator (FLIPR Calcium 4 Assay kit, Molecular Devices) was used to measure intracellular Ca by drug stimulation. 2+ responses were measured.
- Component B HBSS + 20 mM HEPES buffer, pH 7.4
- FLIPR Calcium 4 Assay kit FLIPR Calcium 4 Assay kit, Molecular Devices
- the fluorescence value was measured every 2 seconds for 90 seconds after addition of fentanyl, compound 3F, or compound 3L, which is an opioid ⁇ receptor agonist.
- compound 3F or naloxone which is an opioid ⁇ receptor antagonist, was added, allowed to stand in the device for 30 minutes, then fentanyl (0.025 ⁇ M) was added, and the fluorescence value was similarly measured. was measured.
- Flexstation 3 (Molecular Devices) was used for fluorescence measurement, and the measurement conditions were an excitation wavelength of 485 nm, a fluorescence wavelength of 525 nm, and a cutoff wavelength of 515 nm.
- SOFTMAX PRO software (Molecular Devices) was used for data analysis.
- FIG. 2 also shows dose-response curves when fentanyl was added after pretreatment with compound 3F (3F) or naloxone (NLX).
- 3F 3F
- NLX naloxone
- Example 2 Evaluation of in vivo opioid receptor antagonism of compound 3F> To evaluate the in vivo opioid receptor antagonism of Compound 3F, behavioral pharmacological analysis in mice was performed. ICR male mice (Jcl, 20-25 g, CLEA Japan, Inc.) were used for behavioral pharmacological experiments.
- SAL physiological saline
- FIG. 3A shows the time course of the amount of exercise every 10 minutes after administration of morphine
- FIG. 3B shows the total amount of exercise for 120 minutes after administration of morphine.
- morphine administration significantly increased locomotion peaking at 30 minutes after administration, confirming the prokinetic action of morphine.
- pretreatment with compound 3F or naloxone significantly inhibited the prokinetic effect of morphine ( ## p ⁇ 0.01). This result confirmed that compound 3F exhibited opioid receptor antagonism in vivo.
- Step 3 Optical resolution of compound 5 Since compound 5 is racemic, each atropisomer was separated and isolated by chiral high performance liquid chromatography (HPLC).
- the atropisomer with a faster elution time is designated as compound 5F
- the atropisomer with a later elution time is designated as compound 5L.
- the enantiomeric excess of compound 5F and compound 5L was 99.9% ee.
- the activation free energy value ⁇ G ⁇ between compound 5F and compound 5L was 130.6 kJ/mol (80° C., toluene).
- [ ⁇ ] D 20 (5 L): ⁇ 46.175° (c 1.00, MeOH)
- ⁇ Test Example 3 Evaluation of in vitro opioid ⁇ receptor activity and opioid ⁇ receptor antagonistic activity of compound 5F and compound 5L>
- Opioid ⁇ receptor-expressing cells (CHO- ⁇ cells) were suspended in a nutritive mixture/Ham's F-12 medium containing 10% FBS, and seeded in a 96-well plate at 5.0 ⁇ 10 4 cells/well. , 37° C., 5.0% CO 2 . After 24 hours, the medium was replaced with 100 ⁇ L/well of Component B (HBSS + 20 mM HEPES buffer, pH 7.4), and a calcium-sensitive fluorescent indicator (FLIPR Calcium 4 Assay kit, Molecular Devices) was used to measure intracellular Ca by drug stimulation. 2+ responses were measured.
- Component B HBSS + 20 mM HEPES buffer, pH 7.4
- FLIPR Calcium 4 Assay kit FLIPR Calcium 4 Assay kit, Molecular Devices
- fluorescence values were measured every 2 seconds for 90 seconds after addition of compound 5F or compound 5L. Further, for opioid receptor antagonism, compound 5F or naloxone, which is an opioid ⁇ receptor antagonist, was added and allowed to stand in the device for 30 minutes. was added, and the fluorescence value was measured in the same manner. Flexstation 3 (Molecular Devices) was used for fluorescence measurement, and the measurement conditions were an excitation wavelength of 485 nm, a fluorescence wavelength of 525 nm, and a cutoff wavelength of 515 nm. SOFTMAX PRO software (Molecular Devices) was used for data analysis.
- FIG. 5 Also shown in FIG. 5 is the dose-response curve when fentanyl was added after pretreatment with compound 5F (5F) or naloxone (NLX).
- 5F compound 5F
- NLX naloxone
- IC 50 value 50% inhibitory concentration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided are an opioid receptor antagonist, which contains, as an active ingredient, one atropisomer between a pair of atropisomers of a compound represented by formula (1), said atropisomer having an opioid receptor antagonistic action, or a pharmacologically acceptable salt thereof, and a pharmaceutical composition. In formula (1), R1 represents a heteroaryl group, etc. and R2 and R3 independently represent an alkyl group, etc.
Description
本発明は、新規なオピオイド受容体拮抗剤及び医薬組成物に関する。
The present invention relates to novel opioid receptor antagonists and pharmaceutical compositions.
フェンタニルは、下記式で表される合成オピオイドμ受容体作用薬であり、麻薬系の鎮痛薬としてがん性疼痛の治療等に使用されている。フェンタニルは、強い鎮痛作用を有する反面、安全域が狭く、副作用が出やすいという問題がある。
Fentanyl is a synthetic opioid μ receptor agonist represented by the following formula, and is used as a narcotic analgesic to treat cancer pain. While fentanyl has a strong analgesic effect, it has a narrow safety margin and is prone to side effects.
近年、特に米国において、フェンタニル等のオピオイド系薬物の処方が増加する結果、多くの依存症患者を生み出し、過剰摂取による死亡が交通事故による死亡を上回るほど増加する状況となっている。また、違法に合成された新規オピオイド系薬物も次々に登場しており、過剰摂取による問題は深刻さを増す一方である。このような一連の問題はオピオイドクライシスと称され、大きな社会問題となっている。
In recent years, especially in the United States, the increase in prescriptions for opioid drugs such as fentanyl has resulted in the creation of many addicted patients, and the situation is such that overdose deaths exceed deaths in traffic accidents. In addition, illegally synthesized new opioid drugs are appearing one after another, and the problem of overdose is becoming more and more serious. Such a series of problems is called an opioid crisis, and has become a major social problem.
現在、オピオイド系薬物による副作用や中毒症状に対する治療薬としては、オピオイド受容体拮抗薬であるナロキソン、ナルトレキソン、ナルデメジン等が知られている。また、その他のオピオイド受容体拮抗薬も幾つか提案されている(例えば、特許文献1参照)。
Currently, naloxone, naltrexone, naldemedine, etc., which are opioid receptor antagonists, are known as therapeutic agents for side effects and addictive symptoms caused by opioid drugs. In addition, some other opioid receptor antagonists have also been proposed (see, for example, Patent Document 1).
本発明は、新規なオピオイド受容体拮抗剤及び医薬組成物を提供することを課題とする。
An object of the present invention is to provide a novel opioid receptor antagonist and pharmaceutical composition.
上記課題を解決するための具体的な手段には、以下の実施態様が含まれる。
<1> 下記式(1)で表される化合物が有する一対のアトロプ異性体のうち、オピオイド受容体拮抗作用を有する一方のアトロプ異性体又はその薬理学的に許容される塩を有効成分として含有するオピオイド受容体拮抗剤。 Specific means for solving the above problems include the following embodiments.
<1> Containing as an active ingredient one atropisomer having an opioid receptor antagonistic action or a pharmacologically acceptable salt thereof among a pair of atropisomers possessed by the compound represented by the following formula (1) opioid receptor antagonists.
<1> 下記式(1)で表される化合物が有する一対のアトロプ異性体のうち、オピオイド受容体拮抗作用を有する一方のアトロプ異性体又はその薬理学的に許容される塩を有効成分として含有するオピオイド受容体拮抗剤。 Specific means for solving the above problems include the following embodiments.
<1> Containing as an active ingredient one atropisomer having an opioid receptor antagonistic action or a pharmacologically acceptable salt thereof among a pair of atropisomers possessed by the compound represented by the following formula (1) opioid receptor antagonists.
<2> 前記式(1)中のR1がヘテロアリール基であり、R2及びR3がそれぞれ独立にアルキル基である、<1>に記載のオピオイド受容体拮抗剤。
<2> The opioid receptor antagonist according to <1>, wherein R 1 in formula (1) is a heteroaryl group, and R 2 and R 3 are each independently an alkyl group.
<3> オピオイドμ受容体に対して拮抗作用を示す、<1>又は<2>に記載のオピオイド受容体拮抗剤。
<3> The opioid receptor antagonist according to <1> or <2>, which exhibits an antagonistic effect on opioid μ receptors.
<4> 下記式(2)で表され、且つ、クロロホルムに溶解したときのナトリウムD線に対する20℃における比旋光度が正の値を示すアトロプ異性体を前記有効成分として含有する、<1>~<3>のいずれか1項に記載のオピオイド受容体拮抗剤。
<4> Contains, as the active ingredient, an atropisomer represented by the following formula (2) and having a positive specific rotation at 20°C with respect to the sodium D line when dissolved in chloroform, <1> ~ The opioid receptor antagonist according to any one of <3>.
<5> 下記式(3)で表され、且つ、メタノールに溶解したときのナトリウムD線に対する20℃における比旋光度が正の値を示すアトロプ異性体を前記有効成分として含有する、<1>~<3>のいずれか1項に記載のオピオイド受容体拮抗剤。
<5> Contains, as the active ingredient, an atropisomer represented by the following formula (3) and having a positive specific rotation at 20°C with respect to the sodium D line when dissolved in methanol, <1> ~ The opioid receptor antagonist according to any one of <3>.
<6> 下記式(1)で表される化合物が有する一対のアトロプ異性体のうち、オピオイド受容体拮抗作用を有する一方のアトロプ異性体又はその薬理学的に許容される塩を有効成分として含有する医薬組成物。
<6> Contains, as an active ingredient, one atropisomer having an opioid receptor antagonistic action or a pharmacologically acceptable salt thereof, out of the pair of atropisomers possessed by the compound represented by the following formula (1) A pharmaceutical composition for
<7> 下記式(2)で表され、且つ、クロロホルムに溶解したときのナトリウムD線に対する20℃における比旋光度が正の値を示す化合物。
<7> A compound represented by the following formula (2) and showing a positive specific rotation at 20°C with respect to the sodium D line when dissolved in chloroform.
<8> 下記式(3)で表され、且つ、メタノールに溶解したときのナトリウムD線に対する20℃における比旋光度が正の値を示す化合物。
<8> A compound represented by the following formula (3) and showing a positive specific rotation at 20°C with respect to the sodium D line when dissolved in methanol.
本発明によれば、新規なオピオイド受容体拮抗剤及び医薬組成物を提供することができる。
According to the present invention, novel opioid receptor antagonists and pharmaceutical compositions can be provided.
<オピオイド受容体拮抗剤>
本実施形態に係るオピオイド受容体拮抗剤は、下記式(1)で表される化合物が有する一対のアトロプ異性体のうち、オピオイド受容体拮抗作用を有する一方のアトロプ異性体(以下、「特定アトロプ異性体」ともいう。)又はその薬理学的に許容される塩を有効成分として含有する。 <Opioid receptor antagonist>
The opioid receptor antagonist according to the present embodiment is one atropisomer having opioid receptor antagonistic activity among a pair of atropisomers possessed by the compound represented by the following formula (1) (hereinafter referred to as "specific atropisomer isomer”) or a pharmacologically acceptable salt thereof as an active ingredient.
本実施形態に係るオピオイド受容体拮抗剤は、下記式(1)で表される化合物が有する一対のアトロプ異性体のうち、オピオイド受容体拮抗作用を有する一方のアトロプ異性体(以下、「特定アトロプ異性体」ともいう。)又はその薬理学的に許容される塩を有効成分として含有する。 <Opioid receptor antagonist>
The opioid receptor antagonist according to the present embodiment is one atropisomer having opioid receptor antagonistic activity among a pair of atropisomers possessed by the compound represented by the following formula (1) (hereinafter referred to as "specific atropisomer isomer”) or a pharmacologically acceptable salt thereof as an active ingredient.
「アトロプ異性体」とは、軸性又は面性キラリティーに基づく構造異性体をいう。上記式(1)で表される化合物は、2,6位にR2及びR3が結合したベンゼン環における1位の炭素原子と、ピペリジン環の4位に結合した窒素原子との間の結合(炭素-窒素間結合)の回転が立体障害により制限されることにより、軸不斉由来の一対のアトロプ異性体(Ra体及びSa体)を有する。本実施形態に係るオピオイド受容体拮抗剤は、この一対のアトロプ異性体のうち、オピオイド受容体拮抗作用を有する一方のアトロプ異性体又はその薬理学的に許容される塩を有効成分として含有する。上記式(1)で表される化合物が有する一対のアトロプ異性体の両方がオピオイド受容体拮抗作用を有する場合、本実施形態に係るオピオイド受容体拮抗剤は、いずれのアトロプ異性体を含有してもよい。
"Atropisomer" refers to structural isomers based on axial or planar chirality. The compound represented by the above formula (1) is a bond between the carbon atom at position 1 in the benzene ring having R 2 and R 3 at positions 2 and 6 and the nitrogen atom at position 4 of the piperidine ring. It has a pair of atropisomers (Ra form and Sa form) derived from axial asymmetry due to restricted rotation of (carbon-nitrogen bond) due to steric hindrance. Of the pair of atropisomers, the opioid receptor antagonist according to this embodiment contains one atropisomer having opioid receptor antagonistic activity or a pharmacologically acceptable salt thereof as an active ingredient. When both a pair of atropisomers possessed by the compound represented by the above formula (1) have opioid receptor antagonistic activity, the opioid receptor antagonist according to the present embodiment contains any atropisomer. good too.
上記式(1)中、R1は、アルキル基、シクロアルキル基、アルケニル基、アルキニル基、アリール基、非芳香族複素環基、又はヘテロアリール基を示し、置換基を有していてもよい。R2及びR3はそれぞれ独立に、アルキル基、アルケニル基、アルキニル基、アリール基、カルバモイル基、ニトロ基、ハロゲン原子、又は-OR4、-C(=O)R4、-C(=O)OR4、-OC(=O)R4、-NR4
2、若しくは-SR4で表される基を示し、置換基を有していてもよい。R4はそれぞれ独立に、水素原子、アルキル基、シクロアルキル基、アルケニル基、アルキニル基、アリール基、非芳香族複素環基、又はヘテロアリール基を示す。
In the above formula (1), R 1 represents an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a non-aromatic heterocyclic group, or a heteroaryl group, and may have a substituent. . R 2 and R 3 are each independently an alkyl group, alkenyl group, alkynyl group, aryl group, carbamoyl group, nitro group, halogen atom, or -OR 4 , -C(=O)R 4 , -C(=O ) represents a group represented by OR 4 , —OC(=O)R 4 , —NR 4 2 or —SR 4 and may have a substituent. Each R4 independently represents a hydrogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a non-aromatic heterocyclic group, or a heteroaryl group.
アルキル基としては、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、sec-ブチル基、イソブチル基、tert-ブチル基、ペンチル基、イソペンチル基、ヘキシル基等の炭素数1~20、好ましくは炭素数1~10の直鎖状又は分岐鎖状の基が挙げられる。
The alkyl group preferably has 1 to 20 carbon atoms such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, sec-butyl group, isobutyl group, tert-butyl group, pentyl group, isopentyl group and hexyl group. is a linear or branched group having 1 to 10 carbon atoms.
シクロアルキル基としては、シクロプロピル基、シクロブチル基、シクロペンチル基、シクロヘキシル基、ビシクロ[2.2.1]ヘプチル基、ビシクロ[3.2.1]オクチル基、トリシクロ[2.2.1.0]ヘプチル基等の炭素数3~20、好ましくは炭素数3~10の基が挙げられる。
Cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl and tricyclo[2.2.1.0 ] groups having 3 to 20 carbon atoms, preferably 3 to 10 carbon atoms, such as heptyl groups.
アルケニル基としては、ビニル基、アリル基、プロペニル基、イソプロペニル基、ブテニル基、イソブテニル基、1,3-ブタジエニル基、ペンテニル基、ヘキセニル基等の炭素数2~20、好ましくは炭素数2~10の直鎖状又は分岐鎖状の基が挙げられる。
The alkenyl group includes a vinyl group, allyl group, propenyl group, isopropenyl group, butenyl group, isobutenyl group, 1,3-butadienyl group, pentenyl group, hexenyl group, etc., having 2 to 20 carbon atoms, preferably 2 to 2 carbon atoms. Ten linear or branched groups are included.
アルキニル基としては、エチニル基、プロピニル基、ブチニル基、ペンチニル基、ヘキシニル基等の炭素数2~20、好ましくは炭素数2~10の直鎖状又は分岐鎖状の基が挙げられる。
The alkynyl group includes linear or branched groups having 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms, such as ethynyl group, propynyl group, butynyl group, pentynyl group and hexynyl group.
アリール基としては、フェニル基、ナフチル基、アントリル基、フェナントリル基、ピレニル基、フルオレニル基、インデニル基、アセナフチレニル、インダニル基、アセナフテニル基等の単環式又は2~4環の縮合多環式の基が挙げられる。
Aryl groups include monocyclic or 2- to 4-ring condensed polycyclic groups such as phenyl group, naphthyl group, anthryl group, phenanthryl group, pyrenyl group, fluorenyl group, indenyl group, acenaphthylenyl group, indanyl group and acenaphthenyl group. is mentioned.
非芳香族複素環基としては、アゼチジニル基、ピロリジニル基、ピロリニル基、ピペリジル基、テトラヒドロピリジル基、ホモピペリジニル基、オクタヒドロアゾシニル基、イミダゾリジニル基、イミダゾリニル基、ピラゾリジニル基、ピラゾリニル基、ピペラジニル基、ホモピペラジニル基、2-ピペラジノニル基等の単環式の含窒素基;テトラヒドロフラニル基、テトラヒドロピラニル基、ピラニル基等の単環式の含酸素基;モルホリニル基等の単環式の含窒素・酸素基;チオモルホリニル基等の単環式の含窒素・硫黄基;インドリニル基、イソインドリニル基、テトラヒドロキノリニル基、テトラヒドロイソキノリニル基、2,3-ジヒドロベンゾフラニル基、クロマニル基、クロメニル基、イソクロマニル基、1,3-ベンゾジオキソリル基、1,3-ベンゾジオキサニル基、1,4-ベンゾジオキサニル基等の2環式の含酸素基;2,3-ジヒドロベンゾチエニル基等の2環式の含硫黄基;ベンゾモルホリニル基、ジヒドロピラノピリジル基、ジヒドロジオキシノピリジル基、ジヒドロピリドオキサジニル基等の2環式の含窒素・酸素基;2-アザスピロ[3.3]オクチル基、2-オキサスピロ[3.3]オクチル基、6-アザ-2-オキサスピロ[3.3]オクチル基、1-アザスピロ[4.5]デシル基、1-オキサスピロ[4.5]デシル基等のヘテロ環式スピロ環基;などが挙げられる。
Non-aromatic heterocyclic groups include azetidinyl, pyrrolidinyl, pyrrolinyl, piperidyl, tetrahydropyridyl, homopiperidinyl, octahydroazocinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, and homopiperazinyl. monocyclic nitrogen-containing groups such as groups, 2-piperazinonyl groups; monocyclic oxygen-containing groups such as tetrahydrofuranyl groups, tetrahydropyranyl groups and pyranyl groups; monocyclic nitrogen-containing/oxygen groups such as morpholinyl groups monocyclic nitrogen-sulfur groups such as a thiomorpholinyl group; Bicyclic oxygen-containing groups such as isochromanyl group, 1,3-benzodioxolyl group, 1,3-benzodioxanyl group, 1,4-benzodioxanyl group; 2,3-dihydrobenzothienyl group bicyclic sulfur-containing groups such as; [3.3]octyl group, 2-oxaspiro[3.3]octyl group, 6-aza-2-oxaspiro[3.3]octyl group, 1-azaspiro[4.5]decyl group, 1-oxaspiro[4 .5] a heterocyclic spirocyclic group such as a decyl group;
ヘテロアリール基としては、ピロリル基、ピリジル基、イミダゾリル基、ピラゾリル基、ピラジニル基、ピリダジニル基、ピリミジニル基、トリアゾリル基、テトラゾリル基等の単環式の含窒素基;フラニル基等の単環式の含酸素基;チエニル等の単環式の含硫黄基;オキサゾリル基、イソオキサゾリル基、オキサジアゾリル基等の単環式の含窒素・酸素基;チアゾリル基、イソチアゾリル基、チアジアゾリル基等の単環式の含窒素・硫黄基;インドリル基、イソインドリル基、ベンズイミダゾリル基、インダゾリル基、ベンゾトリアゾリル基、テトラヒドロキノリル基、キノリル基、テトラヒドロイソキノリル基、イソキノリル基、キノリジニル基、シンノリニル基、フタラジニル基、キナゾリニル基、キノキサリニル基、ナフチリジニル基、ピロロピリジル基、イミダゾピリジル基、ピラゾロピリジル基、ピリドピラジル基、プリニル基、プテリジニル基等の2環式の含窒素基;ベンゾフラニル基、イソベンゾフラニル基等の2環式の含酸素基;ベンゾチエニル基等の2環式の含硫黄基;ベンゾオキサゾリル基、ベンゾイソオキサゾリル基、ベンゾオキサジアゾリル基等の2環式の含窒素・酸素基;ベンゾチアゾリル基、ベンゾイソチアゾリル基、ベンゾチアジアゾリル基、チアゾロピリジル基等の2環式の含窒素・硫黄基;などが挙げられる。
Heteroaryl groups include monocyclic nitrogen-containing groups such as pyrrolyl, pyridyl, imidazolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazolyl, and tetrazolyl; monocyclic nitrogen-containing groups such as furanyl; Oxygen-containing groups; monocyclic sulfur-containing groups such as thienyl; monocyclic nitrogen-containing and oxygen groups such as oxazolyl, isoxazolyl and oxadiazolyl groups; monocyclic groups such as thiazolyl, isothiazolyl and thiadiazolyl nitrogen/sulfur groups; Bicyclic nitrogen-containing groups such as a quinazolinyl group, quinoxalinyl group, naphthyridinyl group, pyrrolopyridyl group, imidazopyridyl group, pyrazolopyridyl group, pyridopyrazyl group, purinyl group and pteridinyl group; Cyclic oxygen-containing group; Bicyclic sulfur-containing group such as benzothienyl group; Bicyclic nitrogen-containing/oxygen group such as benzoxazolyl group, benzoisoxazolyl group, benzoxadiazolyl group; bicyclic nitrogen-containing and sulfur groups such as a benzothiazolyl group, a benzisothiazolyl group, a benzothiadiazolyl group, and a thiazolopyridyl group;
ハロゲン原子としては、フッ素原子、塩素原子、臭素原子、ヨウ素原子等が挙げられる。
The halogen atom includes a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, and the like.
R1~R3が有していてもよい置換基としては、アルキル基、シクロアルキル基、アルケニル基、アルキニル基、アリール基、非芳香族複素環基、ヘテロアリール基、シアノ基、ハロゲン原子、ヒドロキシ基、アミノ基、ニトロ基、ニトロキシ基、メルカプト基、シアネート基、チオシアネート基、イソチオシアネート基、スルホ基、スルファミノ基、スルフィノ基、スルファモイル基、ホスホ基、ホスホノ基、ボロニル基等が挙げられる。
Examples of substituents that R 1 to R 3 may have include an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a non-aromatic heterocyclic group, a heteroaryl group, a cyano group, a halogen atom, hydroxy group, amino group, nitro group, nitroxy group, mercapto group, cyanate group, thiocyanate group, isothiocyanate group, sulfo group, sulfamino group, sulfino group, sulfamoyl group, phospho group, phosphono group, boronyl group and the like.
上記式(1)で表される化合物の中でも、R1がヘテロアリール基であり、R2及びR3がそれぞれ独立にアルキル基である化合物が好ましい。
Among the compounds represented by formula (1) above, compounds in which R 1 is a heteroaryl group and R 2 and R 3 are each independently an alkyl group are preferred.
上記式(1)で表される化合物が酸性官能基又は塩基性官能基を有する場合、当該化合物は、塩の形態であってもよい。例えば、上記式(1)で表される化合物が酸性官能基を有する場合、当該化合物は、アルカリ金属塩(ナトリウム塩、カリウム塩等)、アルカリ土類金属塩(カルシウム塩、マグネシウム塩等)、アンモニウム塩等の形態であってもよい。また、上記式(1)で表される化合物が塩基性官能基を有する場合、当該化合物は、塩酸、リン酸等の無機酸との塩の形態であってもよく、酢酸、フマル酸、メタンスルホン酸等の有機酸との塩の形態であってもよい。
When the compound represented by formula (1) above has an acidic functional group or a basic functional group, the compound may be in the form of a salt. For example, when the compound represented by the above formula (1) has an acidic functional group, the compound may be an alkali metal salt (sodium salt, potassium salt, etc.), an alkaline earth metal salt (calcium salt, magnesium salt, etc.), It may be in the form of an ammonium salt or the like. In addition, when the compound represented by the above formula (1) has a basic functional group, the compound may be in the form of a salt with an inorganic acid such as hydrochloric acid or phosphoric acid, acetic acid, fumaric acid, methane It may be in the form of a salt with an organic acid such as sulfonic acid.
本実施形態に係るオピオイド受容体拮抗剤の有効成分である特定アトロプ異性体又はその塩は、オピオイド受容体のいずれのタイプに拮抗作用を示すものであってもよいが、少なくともオピオイドμ受容体に対して拮抗作用を示すものが好ましい。特定アトロプ異性体又はその塩のオピオイドμ受容体に対する拮抗作用は、例えば、後述する試験例1に記載する方法に従って50%阻害濃度(IC50値)を測定することにより確認することができる。
The specific atropisomer or a salt thereof, which is the active ingredient of the opioid receptor antagonist according to the present embodiment, may exhibit an antagonistic effect on any type of opioid receptor, but at least on the opioid μ receptor. It is preferable to show an antagonistic action against The antagonistic action of a specific atropisomer or a salt thereof on the opioid μ receptor can be confirmed, for example, by measuring the 50% inhibitory concentration ( IC50 value) according to the method described in Test Example 1 below.
特定アトロプ異性体の中で特に好ましい化合物の一例としては、下記式(2)で表され、且つ、クロロホルムに溶解したときのナトリウムD線(波長589nm)に対する20℃における比旋光度が正の値を示す化合物が挙げられる。式(2)中、-Meはメチル基を示し、-Etはエチル基を示す。この化合物は、後述する試験例1に示すとおり、ナロキソンよりも強力なオピオイドμ受容体拮抗作用を示す。
An example of a particularly preferred compound among the specific atropisomers is represented by the following formula (2) and has a positive specific rotation at 20° C. with respect to the sodium D line (wavelength 589 nm) when dissolved in chloroform. A compound showing In formula (2), -Me represents a methyl group, and -Et represents an ethyl group. This compound exhibits a stronger opioid μ receptor antagonistic activity than naloxone, as shown in Test Example 1 described later.
また、特定アトロプ異性体の中で特に好ましい化合物の他の例としては、下記式(3)で表され、且つ、メタノールに溶解したときのナトリウムD線(波長589nm)に対する20℃における比旋光度が正の値を示す化合物が挙げられる。式(3)中、-Meはメチル基を示す。この化合物は、後述する試験例3に示すとおり、ナロキソンよりは弱いものの、強力なオピオイドμ受容体拮抗作用を示す。
Further, another example of a particularly preferred compound among the specific atropisomers is represented by the following formula (3), and specific rotation at 20° C. with respect to the sodium D line (wavelength 589 nm) when dissolved in methanol is a positive value. In formula (3), -Me represents a methyl group. As shown in Test Example 3 described later, this compound exhibits a strong opioid μ receptor antagonistic activity, though weaker than that of naloxone.
本実施形態に係るオピオイド受容体拮抗剤の有効成分である特定アトロプ異性体又はその塩は、例えば、ラセミ体をキラルカラムクロマトグラフィー等によって光学分割することにより得ることができる。
A specific atropisomer or a salt thereof, which is the active ingredient of the opioid receptor antagonist according to the present embodiment, can be obtained, for example, by optically resolving the racemate by chiral column chromatography or the like.
本実施形態に係るオピオイド受容体拮抗剤は、オピオイド受容体拮抗作用を示す限り、上記式(1)で表される化合物が有する一対のアトロプ異性体のうち、特定アトロプ異性体とは異なる他方のアトロプ異性体又はその塩を含有していてもよい。この場合、特定アトロプ異性体又はその塩の鏡像体過剰率は、0%ee以上であってもよく、20%ee以上であってもよく、40%ee以上であってもよく、60%ee以上であってもよく、80%ee以上であってもよく、90%ee以上であってもよく、95%ee以上であってもよい。
The opioid receptor antagonist according to the present embodiment, of the pair of atropisomers possessed by the compound represented by the above formula (1), is different from the specific atropisomer, as long as it exhibits opioid receptor antagonistic activity. It may contain atropisomers or salts thereof. In this case, the enantiomeric excess of the specific atropisomer or salt thereof may be 0% ee or more, 20% ee or more, 40% ee or more, or 60% ee. 80% ee or more, 90% ee or more, or 95% ee or more.
本実施形態に係るオピオイド受容体拮抗剤は、使用態様に応じて、有効成分以外の他の成分を含有することができる。例えば、本実施形態に係るオピオイド受容体拮抗剤は、薬理学的に許容される担体を含有することができる。
The opioid receptor antagonist according to the present embodiment can contain ingredients other than the active ingredient, depending on the mode of use. For example, the opioid receptor antagonist according to this embodiment can contain a pharmacologically acceptable carrier.
本実施形態に係るオピオイド受容体拮抗剤は、医薬用途に用いるものであってもよく、医薬以外の用途(研究用途等)に用いるものであってもよい。本実施形態に係るオピオイド受容体拮抗剤を医薬用途に用いる場合、剤形、適応等は後述する医薬組成物と同様でよい。
The opioid receptor antagonist according to this embodiment may be used for medical purposes, or may be used for purposes other than medicine (research purposes, etc.). When the opioid receptor antagonist according to this embodiment is used for medical purposes, the dosage form, indications, etc. may be the same as those of the pharmaceutical composition described later.
<医薬組成物>
本実施形態に係る医薬組成物は、上述した特定アトロプ異性体又はその薬理学的に許容される塩を有効成分として含有する。 <Pharmaceutical composition>
The pharmaceutical composition according to this embodiment contains the above-described specific atropisomer or a pharmacologically acceptable salt thereof as an active ingredient.
本実施形態に係る医薬組成物は、上述した特定アトロプ異性体又はその薬理学的に許容される塩を有効成分として含有する。 <Pharmaceutical composition>
The pharmaceutical composition according to this embodiment contains the above-described specific atropisomer or a pharmacologically acceptable salt thereof as an active ingredient.
有効成分である特定アトロプ異性体又はその塩は、オピオイド受容体拮抗作用を有する。このため、本実施形態に係る医薬組成物は、オピオイド受容体拮抗作用が必要とされる症状に適用することができる。例えば、本実施形態に係る医薬組成物は、オピオイド系薬物による副作用(便秘、悪心、嘔吐、掻痒、血圧降下、呼吸抑制、覚醒遅延等)や中毒症状(呼吸抑制等)を改善又は治療するために使用することができる。また、本実施形態に係る医薬組成物は、アルコール依存症の治療補助薬としても使用することができる。
The specific atropisomer or its salt, which is the active ingredient, has opioid receptor antagonistic activity. Therefore, the pharmaceutical composition according to this embodiment can be applied to symptoms requiring opioid receptor antagonism. For example, the pharmaceutical composition according to the present embodiment is used to improve or treat side effects of opioid drugs (constipation, nausea, vomiting, pruritus, hypotension, respiratory depression, delayed awakening, etc.) and toxic symptoms (respiratory depression, etc.). can be used for In addition, the pharmaceutical composition according to this embodiment can also be used as a treatment adjuvant for alcoholism.
本実施形態に係る医薬組成物は、有効成分以外に、薬理学的に許容される担体を含有することが好ましい。薬理学的に許容される担体としては、製剤素材として慣用の有機又は無機の担体が挙げられる。この担体は、固形製剤においては、賦形剤、滑沢剤、結合剤、崩壊剤等として、液状製剤においては、溶剤、溶解補助剤、懸濁化剤、等張化剤、緩衝剤等として配合される。また、本実施形態に係る医薬組成物は、防腐剤、抗酸化剤、着色剤等の製剤添加物を含有していてもよい。
The pharmaceutical composition according to this embodiment preferably contains a pharmacologically acceptable carrier in addition to the active ingredient. Pharmaceutically acceptable carriers include organic or inorganic carriers commonly used as pharmaceutical materials. This carrier is used as an excipient, lubricant, binder, disintegrant, etc. in solid formulations, and as a solvent, solubilizer, suspending agent, tonicity agent, buffer, etc. in liquid formulations. blended. In addition, the pharmaceutical composition according to this embodiment may contain formulation additives such as preservatives, antioxidants and coloring agents.
本実施形態に係る医薬組成物の剤形は特に制限されない。医薬組成物の剤形としては、錠剤、カプセル剤、乳剤、懸濁剤等の経口剤;注射剤、点滴剤、点鼻剤、外用剤等の非経口剤;などが挙げられる。
The dosage form of the pharmaceutical composition according to this embodiment is not particularly limited. Dosage forms of the pharmaceutical composition include oral agents such as tablets, capsules, emulsions and suspensions; parenteral agents such as injections, drops, nasal drops and external preparations; and the like.
本実施形態に係る医薬組成物の投与量は、投与対象、投与経路、症状等に応じて適宜決定される。
The dosage of the pharmaceutical composition according to this embodiment is appropriately determined according to the administration subject, administration route, symptoms, and the like.
以下、実施例によって本発明をより具体的に説明するが、本発明はこれらの実施例によって制限されるものではない。
The present invention will be described in more detail below with reference to examples, but the present invention is not limited by these examples.
<合成例1:化合物3F及び化合物3Lの合成>
(工程1:化合物2の合成) <Synthesis Example 1: Synthesis ofCompound 3F and Compound 3L>
(Step 1: Synthesis of compound 2)
(工程1:化合物2の合成) <Synthesis Example 1: Synthesis of
(Step 1: Synthesis of compound 2)
市販の1-(2-フェニルエチル)-4-ピペリドン(化合物1)(1.016g,5mmol)にエタノール(20mL)を加えて溶解し、酢酸(343μL,6mmol)及び2-エチル-6-メチルアニリン(1.394mL,10mmol)を加えた。反応溶液を加熱還流下で80分間撹拌した後、25℃に冷却し、シアノ水素化ホウ素ナトリウム(0.628g,10mmol)をゆっくりと加えた。加熱還流下でさらに21時間撹拌した後、2N 水酸化ナトリウム水溶液を加え、ロータリーエバポレーターで濃縮した。濃縮物を酢酸エチルにより抽出し、2N 水酸化ナトリウム水溶液及び飽和食塩水で洗浄した。Na2SO4を加えて乾燥させた後、濃縮した。粗生成物をカラムクロマトグラフィー(酢酸エチル/ジクロロメタン=1/1)により精製し、化合物2を油状物質(収量:1.037g;64%)として得た。化合物2の物性値は以下のとおりである。
Ethanol (20 mL) was added to commercially available 1-(2-phenylethyl)-4-piperidone (compound 1) (1.016 g, 5 mmol) to dissolve it, and acetic acid (343 μL, 6 mmol) and 2-ethyl-6-methyl Aniline (1.394 mL, 10 mmol) was added. After the reaction solution was stirred under reflux for 80 minutes, it was cooled to 25° C. and sodium cyanoborohydride (0.628 g, 10 mmol) was slowly added. After further stirring for 21 hours while heating under reflux, 2N aqueous sodium hydroxide solution was added, and the mixture was concentrated using a rotary evaporator. The concentrate was extracted with ethyl acetate and washed with 2N sodium hydroxide aqueous solution and saturated brine. Na 2 SO 4 was added to dry and then concentrated. The crude product was purified by column chromatography (ethyl acetate/dichloromethane=1/1) to give compound 2 as an oil (yield: 1.037 g; 64%). The physical property values of compound 2 are as follows.
化合物2:
IR(ATR):3373cm-1(NH);
1H NMR(600MHz,CDCl3):δ=7.28(t,J=7.2Hz,2H),7.19(m,3H),7.02(d,J=7.2Hz,1H),6.99(d,J=7.2Hz,1H),6.86(t,J=7.2Hz,1H),2.98(m,3H),2.80(m,2H),2.64(q,J=7.2Hz,2H),2.59(m,2H),2.28(s,3H),2.03(td,J=12.0,1.8Hz,2H),1.95(m,2H),1.50(ddd,J=24.0,12.0,3.0Hz,2H),1.23(t,J=7.2Hz,3H);
13C NMR(150MHz,CDCl3):δ=144.0,140.4,135.2,129.6,128.7,128.7,128.4,126.6,126.0,121.8,60.5,54.9,53.1,33.9,24.5,19.2,14.4;
HRMS(ESI):m/z calcd for C22H31N2:323.2482(M+H)+,found:323.2481. Compound 2:
IR (ATR): 3373 cm −1 (NH);
1 H NMR (600 MHz, CDCl 3 ): δ = 7.28 (t, J = 7.2 Hz, 2H), 7.19 (m, 3H), 7.02 (d, J = 7.2Hz, 1H) , 6.99 (d, J=7.2 Hz, 1 H), 6.86 (t, J=7.2 Hz, 1 H), 2.98 (m, 3 H), 2.80 (m, 2 H), 2 .64 (q, J=7.2Hz, 2H), 2.59 (m, 2H), 2.28 (s, 3H), 2.03 (td, J=12.0, 1.8Hz, 2H) , 1.95 (m, 2H), 1.50 (ddd, J=24.0, 12.0, 3.0 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H);
13 C NMR (150 MHz, CDCl 3 ): δ=144.0, 140.4, 135.2, 129.6, 128.7, 128.7, 128.4, 126.6, 126.0, 121. 8, 60.5, 54.9, 53.1, 33.9, 24.5, 19.2, 14.4;
HRMS (ESI) : m/z calcd for C22H31N2 : 323.2482 (M+H) <+> , found: 323.2481.
IR(ATR):3373cm-1(NH);
1H NMR(600MHz,CDCl3):δ=7.28(t,J=7.2Hz,2H),7.19(m,3H),7.02(d,J=7.2Hz,1H),6.99(d,J=7.2Hz,1H),6.86(t,J=7.2Hz,1H),2.98(m,3H),2.80(m,2H),2.64(q,J=7.2Hz,2H),2.59(m,2H),2.28(s,3H),2.03(td,J=12.0,1.8Hz,2H),1.95(m,2H),1.50(ddd,J=24.0,12.0,3.0Hz,2H),1.23(t,J=7.2Hz,3H);
13C NMR(150MHz,CDCl3):δ=144.0,140.4,135.2,129.6,128.7,128.7,128.4,126.6,126.0,121.8,60.5,54.9,53.1,33.9,24.5,19.2,14.4;
HRMS(ESI):m/z calcd for C22H31N2:323.2482(M+H)+,found:323.2481. Compound 2:
IR (ATR): 3373 cm −1 (NH);
1 H NMR (600 MHz, CDCl 3 ): δ = 7.28 (t, J = 7.2 Hz, 2H), 7.19 (m, 3H), 7.02 (d, J = 7.2Hz, 1H) , 6.99 (d, J=7.2 Hz, 1 H), 6.86 (t, J=7.2 Hz, 1 H), 2.98 (m, 3 H), 2.80 (m, 2 H), 2 .64 (q, J=7.2Hz, 2H), 2.59 (m, 2H), 2.28 (s, 3H), 2.03 (td, J=12.0, 1.8Hz, 2H) , 1.95 (m, 2H), 1.50 (ddd, J=24.0, 12.0, 3.0 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H);
13 C NMR (150 MHz, CDCl 3 ): δ=144.0, 140.4, 135.2, 129.6, 128.7, 128.7, 128.4, 126.6, 126.0, 121. 8, 60.5, 54.9, 53.1, 33.9, 24.5, 19.2, 14.4;
HRMS (ESI) : m/z calcd for C22H31N2 : 323.2482 (M+H) <+> , found: 323.2481.
(工程2:化合物3の合成)
(Step 2: Synthesis of Compound 3)
化合物2(129.0mg,0.4mmol)をDMF(4mL)に溶解し、0℃に冷却した。その後、水素化ナトリウム(60% in oil)(24mg,0.6mmol)を加えた。反応溶液を25℃で25分間撹拌した後、2-フロイルクロリド(118μL,1.2mmol)を加えた。25℃で18時間撹拌した後、2N 水酸化ナトリウム水溶液を加え、ジエチルエーテルにより抽出した。有機層を2N 水酸化ナトリウム水溶液及び飽和食塩水で洗浄し、Na2SO4を加えて乾燥させ、濃縮した。粗生成物をシリカゲルカラムクロマトグラフィー(酢酸エチル/ジクロロメタン=2/1)により精製し、化合物3を白色粉末(収量:144.5mg;87%)として得た。化合物3の物性値は以下のとおりである。
Compound 2 (129.0 mg, 0.4 mmol) was dissolved in DMF (4 mL) and cooled to 0°C. Then sodium hydride (60% in oil) (24mg, 0.6mmol) was added. After the reaction solution was stirred at 25° C. for 25 minutes, 2-furoyl chloride (118 μL, 1.2 mmol) was added. After stirring at 25° C. for 18 hours, 2N aqueous sodium hydroxide solution was added and the mixture was extracted with diethyl ether. The organic layer was washed with 2N aqueous sodium hydroxide solution and saturated brine, dried by adding Na 2 SO 4 and concentrated. The crude product was purified by silica gel column chromatography (ethyl acetate/dichloromethane=2/1) to obtain compound 3 as a white powder (yield: 144.5 mg; 87%). The physical property values of compound 3 are as follows.
化合物3:
mp:141-142℃;
IR(ATR):1630cm-1(CO);
1H-NMR(600MHz,CDCl3):δ=7.35(d,J=1.8Hz,1H),7.26(dt,J=10.2,7.8Hz,3H),7.18(m,4H),7.12(d,J=7.2Hz,1H),6.12(dd,J=3.6,1.8Hz,1H),5.27(dd,J=3.6,1.8Hz,1H),4.31(tt,J=12.0,3.6Hz,1H),3.04(m,2H),2.76(m,2H),2.54(m,4H),2.21(s,3H),2.17(td,J=12.0,1.8Hz,2H),2.04(ddt,J=22.2,12.0,3.6Hz,2H),1.59(m,2H),1.07(t,J=7.8Hz,3H);
13C NMR(150MHz,CDCl3):δ=159.6,147.4,144.4,143.5,140.3,137.9,137.8,128.7,128.7,128.6,128.3,126.5,126.0,114.8,111.0,60.4,57.0,53.2,33.8,30.1,30.0,24.1,19.1,14.0;several signals overlap;
HRMS(ESI):m/z calcd for C27H33N2O2:417.2537(M+H)+,found:417.2537. Compound 3:
mp: 141-142°C;
IR (ATR): 1630 cm -1 (CO);
1 H-NMR (600 MHz, CDCl 3 ): δ=7.35 (d, J=1.8 Hz, 1 H), 7.26 (dt, J=10.2, 7.8 Hz, 3 H), 7.18 (m, 4H), 7.12 (d, J=7.2Hz, 1H), 6.12 (dd, J=3.6, 1.8Hz, 1H), 5.27 (dd, J=3. 6, 1.8Hz, 1H), 4.31 (tt, J = 12.0, 3.6Hz, 1H), 3.04 (m, 2H), 2.76 (m, 2H), 2.54 ( m, 4H), 2.21 (s, 3H), 2.17 (td, J = 12.0, 1.8 Hz, 2H), 2.04 (ddt, J = 22.2, 12.0, 3 .6 Hz, 2 H), 1.59 (m, 2 H), 1.07 (t, J = 7.8 Hz, 3 H);
13 C NMR (150 MHz, CDCl 3 ): δ=159.6, 147.4, 144.4, 143.5, 140.3, 137.9, 137.8, 128.7, 128.7, 128. 6, 128.3, 126.5, 126.0, 114.8, 111.0, 60.4, 57.0, 53.2, 33.8, 30.1, 30.0, 24.1, 19.1, 14.0; several signals overlap;
HRMS (ESI): m/z calcd for C27H33N2O2: 417.2537 (M+H)<+> , found : 417.2537 .
mp:141-142℃;
IR(ATR):1630cm-1(CO);
1H-NMR(600MHz,CDCl3):δ=7.35(d,J=1.8Hz,1H),7.26(dt,J=10.2,7.8Hz,3H),7.18(m,4H),7.12(d,J=7.2Hz,1H),6.12(dd,J=3.6,1.8Hz,1H),5.27(dd,J=3.6,1.8Hz,1H),4.31(tt,J=12.0,3.6Hz,1H),3.04(m,2H),2.76(m,2H),2.54(m,4H),2.21(s,3H),2.17(td,J=12.0,1.8Hz,2H),2.04(ddt,J=22.2,12.0,3.6Hz,2H),1.59(m,2H),1.07(t,J=7.8Hz,3H);
13C NMR(150MHz,CDCl3):δ=159.6,147.4,144.4,143.5,140.3,137.9,137.8,128.7,128.7,128.6,128.3,126.5,126.0,114.8,111.0,60.4,57.0,53.2,33.8,30.1,30.0,24.1,19.1,14.0;several signals overlap;
HRMS(ESI):m/z calcd for C27H33N2O2:417.2537(M+H)+,found:417.2537. Compound 3:
mp: 141-142°C;
IR (ATR): 1630 cm -1 (CO);
1 H-NMR (600 MHz, CDCl 3 ): δ=7.35 (d, J=1.8 Hz, 1 H), 7.26 (dt, J=10.2, 7.8 Hz, 3 H), 7.18 (m, 4H), 7.12 (d, J=7.2Hz, 1H), 6.12 (dd, J=3.6, 1.8Hz, 1H), 5.27 (dd, J=3. 6, 1.8Hz, 1H), 4.31 (tt, J = 12.0, 3.6Hz, 1H), 3.04 (m, 2H), 2.76 (m, 2H), 2.54 ( m, 4H), 2.21 (s, 3H), 2.17 (td, J = 12.0, 1.8 Hz, 2H), 2.04 (ddt, J = 22.2, 12.0, 3 .6 Hz, 2 H), 1.59 (m, 2 H), 1.07 (t, J = 7.8 Hz, 3 H);
13 C NMR (150 MHz, CDCl 3 ): δ=159.6, 147.4, 144.4, 143.5, 140.3, 137.9, 137.8, 128.7, 128.7, 128. 6, 128.3, 126.5, 126.0, 114.8, 111.0, 60.4, 57.0, 53.2, 33.8, 30.1, 30.0, 24.1, 19.1, 14.0; several signals overlap;
HRMS (ESI): m/z calcd for C27H33N2O2: 417.2537 (M+H)<+> , found : 417.2537 .
(工程3:化合物3の光学分割)
化合物3はラセミ体であるため、キラル高速液体クロマトグラフィー(HPLC)により、各アトロプ異性体を分離及び単離した。HPLCの分離条件は以下のとおりである。
-HPLC条件-
カラム:CHIRALPAK IG(Φ=4.6mm)
移動相:30%エタノール/ヘキサン
流速:0.5mL/分
温度:25℃
溶出時間:25.7分、30.8分 (Step 3: Optical resolution of compound 3)
Since compound 3 is racemic, each atropisomer was separated and isolated by chiral high performance liquid chromatography (HPLC). The HPLC separation conditions are as follows.
- HPLC conditions -
Column: CHIRALPAK IG (Φ=4.6mm)
Mobile phase: 30% ethanol/hexane Flow rate: 0.5 mL/min Temperature: 25°C
Elution time: 25.7 minutes, 30.8 minutes
化合物3はラセミ体であるため、キラル高速液体クロマトグラフィー(HPLC)により、各アトロプ異性体を分離及び単離した。HPLCの分離条件は以下のとおりである。
-HPLC条件-
カラム:CHIRALPAK IG(Φ=4.6mm)
移動相:30%エタノール/ヘキサン
流速:0.5mL/分
温度:25℃
溶出時間:25.7分、30.8分 (Step 3: Optical resolution of compound 3)
Since compound 3 is racemic, each atropisomer was separated and isolated by chiral high performance liquid chromatography (HPLC). The HPLC separation conditions are as follows.
- HPLC conditions -
Column: CHIRALPAK IG (Φ=4.6mm)
Mobile phase: 30% ethanol/hexane Flow rate: 0.5 mL/min Temperature: 25°C
Elution time: 25.7 minutes, 30.8 minutes
キラルHPLCにより分離及び単離された一対のアトロプ異性体のうち、溶出時間が早いアトロプ異性体を化合物3Fと表記し、溶出時間が遅いアトロプ異性体を化合物3Lと表記する。化合物3Fの鏡像体過剰率は97.9%eeであり、化合物3Lの鏡像体過剰率は96.9%eeであった。また、化合物3Fと化合物3Lとの間の活性化自由エネルギー値ΔG‡は126.7kJ/mol(80℃,トルエン)であった。化合物3F及び化合物3Lの比旋光度は以下のとおりである。
[α]D 20(3F):+4.50°(c=0.03,CHCl3)
[α]D 20(3L):-4.43°(c=0.15,CHCl3) Of the pair of atropisomers separated and isolated by chiral HPLC, the atropisomer with a faster elution time is designated ascompound 3F, and the atropisomer with a later elution time is designated as compound 3L. The enantiomeric excess of compound 3F was 97.9% ee, and the enantiomeric excess of compound 3L was 96.9% ee. Also, the activation free energy value ΔG ‡ between compound 3F and compound 3L was 126.7 kJ/mol (80° C., toluene). The specific rotations of compound 3F and compound 3L are as follows.
[α] D20 (3F): +4.50° (c= 0.03 , CHCl3 )
[α] D 20 (3 L): −4.43° (c=0.15, CHCl 3 )
[α]D 20(3F):+4.50°(c=0.03,CHCl3)
[α]D 20(3L):-4.43°(c=0.15,CHCl3) Of the pair of atropisomers separated and isolated by chiral HPLC, the atropisomer with a faster elution time is designated as
[α] D20 (3F): +4.50° (c= 0.03 , CHCl3 )
[α] D 20 (3 L): −4.43° (c=0.15, CHCl 3 )
<試験例1:化合物3F及び化合物3Lのin vitroにおけるオピオイドμ受容体作用及びオピオイドμ受容体拮抗作用の評価>
オピオイドμ受容体発現細胞(CHO-μ細胞)を10% FBS含有nutrient mixture/Ham’s F-12培地に懸濁し、5.0×104細胞/ウェルとなるように96ウェルプレートに播種し、37℃、5.0% CO2の条件下にて培養した。24時間後、培地を100μL/ウェルのComponent B(HBSS+20mM HEPESバッファー、pH7.4)に置換し、カルシウム感受性蛍光指示薬(FLIPR Calcium 4 Assay kit、Molecular Devices社)を用いて、薬物刺激による細胞内Ca2+応答を測定した。具体的に、オピオイド受容体作用については、オピオイドμ受容体作用薬であるフェンタニル、化合物3F、又は化合物3Lを添加した後、2秒ごとに90秒間に亘って蛍光値を測定した。また、オピオイド受容体拮抗作用については、化合物3F又はオピオイドμ受容体拮抗薬であるナロキソンを添加し、装置内に30分間静置した後、フェンタニル(0.025μM)を添加し、同様に蛍光値を測定した。蛍光測定にはFlexstation 3(Molecular Devices社)を使用し、測定条件は励起波長485nm、蛍光波長525nm、カットオフ波長515nmとした。データの解析には、SOFTMAX PROソフトウェア(Molecular Devices社)を使用した。 <Test Example 1: Evaluation of in vitro opioid μ receptor activity and opioid μ receptor antagonistic activity ofcompound 3F and compound 3L>
Opioid μ receptor-expressing cells (CHO-μ cells) were suspended in a nutritive mixture/Ham's F-12 medium containing 10% FBS, and seeded in a 96-well plate at 5.0×10 4 cells/well. , 37° C., 5.0% CO 2 . After 24 hours, the medium was replaced with 100 µL/well of Component B (HBSS + 20 mM HEPES buffer, pH 7.4), and a calcium-sensitive fluorescent indicator (FLIPR Calcium 4 Assay kit, Molecular Devices) was used to measure intracellular Ca by drug stimulation. 2+ responses were measured. Specifically, for opioid receptor action, the fluorescence value was measured every 2 seconds for 90 seconds after addition of fentanyl, compound 3F, or compound 3L, which is an opioid μ receptor agonist. In addition, for opioid receptor antagonism, compound 3F or naloxone, which is an opioid μ receptor antagonist, was added, allowed to stand in the device for 30 minutes, then fentanyl (0.025 μM) was added, and the fluorescence value was similarly measured. was measured. Flexstation 3 (Molecular Devices) was used for fluorescence measurement, and the measurement conditions were an excitation wavelength of 485 nm, a fluorescence wavelength of 525 nm, and a cutoff wavelength of 515 nm. SOFTMAX PRO software (Molecular Devices) was used for data analysis.
オピオイドμ受容体発現細胞(CHO-μ細胞)を10% FBS含有nutrient mixture/Ham’s F-12培地に懸濁し、5.0×104細胞/ウェルとなるように96ウェルプレートに播種し、37℃、5.0% CO2の条件下にて培養した。24時間後、培地を100μL/ウェルのComponent B(HBSS+20mM HEPESバッファー、pH7.4)に置換し、カルシウム感受性蛍光指示薬(FLIPR Calcium 4 Assay kit、Molecular Devices社)を用いて、薬物刺激による細胞内Ca2+応答を測定した。具体的に、オピオイド受容体作用については、オピオイドμ受容体作用薬であるフェンタニル、化合物3F、又は化合物3Lを添加した後、2秒ごとに90秒間に亘って蛍光値を測定した。また、オピオイド受容体拮抗作用については、化合物3F又はオピオイドμ受容体拮抗薬であるナロキソンを添加し、装置内に30分間静置した後、フェンタニル(0.025μM)を添加し、同様に蛍光値を測定した。蛍光測定にはFlexstation 3(Molecular Devices社)を使用し、測定条件は励起波長485nm、蛍光波長525nm、カットオフ波長515nmとした。データの解析には、SOFTMAX PROソフトウェア(Molecular Devices社)を使用した。 <Test Example 1: Evaluation of in vitro opioid μ receptor activity and opioid μ receptor antagonistic activity of
Opioid μ receptor-expressing cells (CHO-μ cells) were suspended in a nutritive mixture/Ham's F-12 medium containing 10% FBS, and seeded in a 96-well plate at 5.0×10 4 cells/well. , 37° C., 5.0% CO 2 . After 24 hours, the medium was replaced with 100 µL/well of Component B (HBSS + 20 mM HEPES buffer, pH 7.4), and a calcium-sensitive fluorescent indicator (
化合物3F(3F)、化合物3L(3L)、又はフェンタニル(FN)を添加したときの用量反応曲線を図1に示す。図1から分かるように、フェンタニルを添加した場合には、濃度依存的に蛍光値の増加が確認され、50%効果濃度(EC50値)は4.79×10-9Mであった。化合物3Lを添加した場合にも、濃度依存的に蛍光値の増加が確認されたが、50%効果濃度(EC50値)は1.09×10-8Mでありフェンタニルよりも弱く、最大効果はフェンタニルの約60%であった。この結果から、化合物3Lはオピオイドμ受容体部分作用薬であると考えられる。一方、化合物3Fを添加した場合には、蛍光値の増加は確認されなかった。
Dose-response curves for the addition of compound 3F (3F), compound 3L (3L), or fentanyl (FN) are shown in FIG. As can be seen from FIG. 1, when fentanyl was added, a concentration-dependent increase in fluorescence value was confirmed, and the 50% effective concentration (EC 50 value) was 4.79×10 −9 M. Even when compound 3L was added, a concentration-dependent increase in fluorescence value was confirmed, but the 50% effective concentration (EC 50 value) was 1.09×10 −8 M, which was weaker than fentanyl and had the maximum effect. was about 60% of fentanyl. This result suggests that Compound 3L is an opioid μ receptor partial agonist. On the other hand, when Compound 3F was added, no increase in fluorescence value was confirmed.
また、化合物3F(3F)又はナロキソン(NLX)で前処理した後、フェンタニルを添加したときの用量反応曲線を図2に示す。図2から分かるように、フェンタニルの効果は化合物3F及びナロキソンにより濃度依存的に抑制された。50%阻害濃度(IC50値)は、化合物3Fが3.25×10-8M、ナロキソンが1.65×10-7Mであり、化合物3Fの方がナロキソンよりも強力なオピオイドμ受容体拮抗作用を有していた。
FIG. 2 also shows dose-response curves when fentanyl was added after pretreatment with compound 3F (3F) or naloxone (NLX). As can be seen from FIG. 2, the effect of fentanyl was suppressed by compound 3F and naloxone in a dose-dependent manner. The 50% inhibitory concentration ( IC50 value) was 3.25×10 −8 M for compound 3F and 1.65×10 −7 M for naloxone, indicating that compound 3F is a more potent opioid μ receptor than naloxone. had an antagonistic effect.
<試験例2:化合物3Fのin vivoにおけるオピオイド受容体拮抗作用の評価>
化合物3Fのin vivoにおけるオピオイド受容体拮抗作用を評価するため、マウスによる行動薬理学的解析を行った。行動薬理実験には、ICR系雄性マウス(Jcl、20~25g、日本クレア(株))を使用した。 <Test Example 2: Evaluation of in vivo opioid receptor antagonism ofcompound 3F>
To evaluate the in vivo opioid receptor antagonism ofCompound 3F, behavioral pharmacological analysis in mice was performed. ICR male mice (Jcl, 20-25 g, CLEA Japan, Inc.) were used for behavioral pharmacological experiments.
化合物3Fのin vivoにおけるオピオイド受容体拮抗作用を評価するため、マウスによる行動薬理学的解析を行った。行動薬理実験には、ICR系雄性マウス(Jcl、20~25g、日本クレア(株))を使用した。 <Test Example 2: Evaluation of in vivo opioid receptor antagonism of
To evaluate the in vivo opioid receptor antagonism of
3時間の環境適応後、行動薬理実験として、モルヒネの全身投与により誘発される行動変化に対する化合物3F又はオピオイド受容体拮抗薬であるナロキソンの効果を検討した。具体的には、赤外線センサー内蔵の自発運動量測定装置(ACTIMO-100、バイオリサーチセンター(株))を用いて、モルヒネ(Mor)を10mg/kgの投与量で腹腔内投与した後の運動量を投与から120分間に亘って測定した。化合物3F(3F)の投与群(n=12)は、モルヒネ投与の30分前に化合物3Fを2mg/kgの投与量で腹腔内投与した。ナロキソン(NLX)の投与群(n=12)は、モルヒネ投与の30分前にナロキソンを2mg/kgの投与量で腹腔内投与した。コントロールとしては、モルヒネ投与の30分前に生理食塩水(SAL)を腹腔内投与した投与群(n=14)と、薬物の代わりに生理食塩水(SAL)を腹腔内投与した投与群(n=12)とを準備した。
After 3 hours of adaptation to the environment, as a behavioral pharmacological experiment, the effects of compound 3F or naloxone, an opioid receptor antagonist, on behavioral changes induced by systemic administration of morphine were examined. Specifically, using a locomotor activity measuring device (ACTIMO-100, Bio Research Center Co., Ltd.) with a built-in infrared sensor, morphine (Mor) was intraperitoneally administered at a dose of 10 mg/kg, and then the amount of exercise was administered. was measured over a period of 120 minutes. Compound 3F (3F) administration group (n=12) was intraperitoneally administered with compound 3F at a dose of 2 mg/kg 30 minutes before administration of morphine. In the naloxone (NLX) administration group (n=12), naloxone was administered intraperitoneally at a dose of 2 mg/kg 30 minutes before morphine administration. As controls, an administration group (n = 14) that was intraperitoneally administered with physiological saline (SAL) 30 minutes before administration of morphine, and an administration group (n = 14) that was intraperitoneally administered with physiological saline (SAL) instead of the drug (n = 12) were prepared.
モルヒネ投与から10分間毎の運動量の経時変化を図3Aに示し、モルヒネ投与から120分間の総運動量を図3Bに示す。図3A及び図3Bから分かるように、化合物3F又はナロキソンで前処置していない場合には、モルヒネ投与により、投与後30分をピークとして運動量が有意に増加し、モルヒネによる運動促進作用が確認された(**p<0.01)。一方、化合物3F又はナロキソンで前処置した場合には、モルヒネによる運動促進作用が有意に抑制された(##p<0.01)。この結果から、化合物3Fがin vivoでオピオイド受容体拮抗作用を示すことが確認された。
FIG. 3A shows the time course of the amount of exercise every 10 minutes after administration of morphine, and FIG. 3B shows the total amount of exercise for 120 minutes after administration of morphine. As can be seen from FIGS. 3A and 3B, in the absence of pretreatment with compound 3F or naloxone, morphine administration significantly increased locomotion peaking at 30 minutes after administration, confirming the prokinetic action of morphine. ( ** p<0.01). On the other hand, pretreatment with compound 3F or naloxone significantly inhibited the prokinetic effect of morphine ( ## p<0.01). This result confirmed that compound 3F exhibited opioid receptor antagonism in vivo.
<合成例2:化合物5F及び化合物5Lの合成>
(工程1:化合物4の合成) <Synthesis Example 2: Synthesis ofCompound 5F and Compound 5L>
(Step 1: Synthesis of Compound 4)
(工程1:化合物4の合成) <Synthesis Example 2: Synthesis of
(Step 1: Synthesis of Compound 4)
市販の1-(2-フェニルエチル)-4-ピペリドン(化合物1)(203.1mg,1.00mmol)にエタノール(5mL)を加えて溶解し、酢酸(68μL,1.2mmol)及び2-イソプロピル-6-メチルアニリン(310μL,2.01mmol)を加えた。反応溶液を加熱還流下で1時間撹拌した後、25℃に冷却し、シアノ水素化ホウ素ナトリウム(126.1mg,2.01mmol)をゆっくりと加えた。加熱還流下でさらに18時間撹拌した後、2N 水酸化ナトリウム水溶液を加え、ロータリーエバポレーターで濃縮した。濃縮物を酢酸エチルにより抽出し、2N 水酸化ナトリウム水溶液及び飽和食塩水で洗浄した。Na2SO4を加えて乾燥させた後、濃縮した。粗生成物をカラムクロマトグラフィー(ヘキサン/酢酸エチル=1/1)により精製し、化合物4を油状物質(収量:214.0mg;64%)として得た。化合物4の物性値は以下のとおりである。
Commercially available 1-(2-phenylethyl)-4-piperidone (compound 1) (203.1 mg, 1.00 mmol) was dissolved in ethanol (5 mL), and acetic acid (68 μL, 1.2 mmol) and 2-isopropyl -6-Methylaniline (310 μL, 2.01 mmol) was added. After the reaction solution was stirred under reflux with heating for 1 hour, it was cooled to 25° C. and sodium cyanoborohydride (126.1 mg, 2.01 mmol) was slowly added. After further stirring for 18 hours while heating under reflux, 2N aqueous sodium hydroxide solution was added and the mixture was concentrated by a rotary evaporator. The concentrate was extracted with ethyl acetate and washed with 2N sodium hydroxide aqueous solution and saturated brine. Na 2 SO 4 was added to dry and then concentrated. The crude product was purified by column chromatography (hexane/ethyl acetate=1/1) to give compound 4 as an oily substance (yield: 214.0 mg; 64%). The physical property values of compound 4 are as follows.
化合物4:
IR(ATR):3373cm-1(NH);
1H NMR(400MHz,CDCl3):δ=7.28(m,2H),7.19(m,3H),7.09(dd,J=7.3,1.4Hz,1H),6.98(dd,J=7.3,1.4Hz,1H),6.91(t,J=7.3Hz,1H),3.21(sep,J=6.9Hz,1H),3.00(m,2H),2.91(tt,J=11.0,3.9Hz,1H),2.80(m,2H),2.58(m,2H),2.51(brs,1H,NH),2.28(s,3H),1.99(m,4H),1.51(m,2H),1.22(d,J=6.9Hz,6H);
13C NMR(100MHz,CDCl3):δ=143.0,140.9,140.3,130.3,128.6,128.3,128,3,126.0,123.8,122.3,60.5,55.8,53.1,33.9,33.7,27.6,24.0,19.3;
HRMS(ESI):m/z calcd for C23H33N2:337.2638(M+H)+,found:337.2637. Compound 4:
IR (ATR): 3373 cm −1 (NH);
1 H NMR (400 MHz, CDCl 3 ): δ=7.28 (m, 2H), 7.19 (m, 3H), 7.09 (dd, J=7.3, 1.4 Hz, 1H), 6 .98 (dd, J=7.3, 1.4 Hz, 1 H), 6.91 (t, J=7.3 Hz, 1 H), 3.21 (sep, J=6.9 Hz, 1 H), 3. 00 (m, 2H), 2.91 (tt, J = 11.0, 3.9Hz, 1H), 2.80 (m, 2H), 2.58 (m, 2H), 2.51 (brs, 1H, NH), 2.28 (s, 3H), 1.99 (m, 4H), 1.51 (m, 2H), 1.22 (d, J = 6.9 Hz, 6H);
13 C NMR (100 MHz, CDCl 3 ): δ=143.0, 140.9, 140.3, 130.3, 128.6, 128.3, 128, 3, 126.0, 123.8, 122. 3, 60.5, 55.8, 53.1, 33.9, 33.7, 27.6, 24.0, 19.3;
HRMS (ESI): m/z calcd for C23H33N2 : 337.2638 (M+H) <+> , found : 337.2637.
IR(ATR):3373cm-1(NH);
1H NMR(400MHz,CDCl3):δ=7.28(m,2H),7.19(m,3H),7.09(dd,J=7.3,1.4Hz,1H),6.98(dd,J=7.3,1.4Hz,1H),6.91(t,J=7.3Hz,1H),3.21(sep,J=6.9Hz,1H),3.00(m,2H),2.91(tt,J=11.0,3.9Hz,1H),2.80(m,2H),2.58(m,2H),2.51(brs,1H,NH),2.28(s,3H),1.99(m,4H),1.51(m,2H),1.22(d,J=6.9Hz,6H);
13C NMR(100MHz,CDCl3):δ=143.0,140.9,140.3,130.3,128.6,128.3,128,3,126.0,123.8,122.3,60.5,55.8,53.1,33.9,33.7,27.6,24.0,19.3;
HRMS(ESI):m/z calcd for C23H33N2:337.2638(M+H)+,found:337.2637. Compound 4:
IR (ATR): 3373 cm −1 (NH);
1 H NMR (400 MHz, CDCl 3 ): δ=7.28 (m, 2H), 7.19 (m, 3H), 7.09 (dd, J=7.3, 1.4 Hz, 1H), 6 .98 (dd, J=7.3, 1.4 Hz, 1 H), 6.91 (t, J=7.3 Hz, 1 H), 3.21 (sep, J=6.9 Hz, 1 H), 3. 00 (m, 2H), 2.91 (tt, J = 11.0, 3.9Hz, 1H), 2.80 (m, 2H), 2.58 (m, 2H), 2.51 (brs, 1H, NH), 2.28 (s, 3H), 1.99 (m, 4H), 1.51 (m, 2H), 1.22 (d, J = 6.9 Hz, 6H);
13 C NMR (100 MHz, CDCl 3 ): δ=143.0, 140.9, 140.3, 130.3, 128.6, 128.3, 128, 3, 126.0, 123.8, 122. 3, 60.5, 55.8, 53.1, 33.9, 33.7, 27.6, 24.0, 19.3;
HRMS (ESI): m/z calcd for C23H33N2 : 337.2638 (M+H) <+> , found : 337.2637.
(工程2:化合物5の合成)
(Step 2: Synthesis of Compound 5)
化合物4(214.0mg,0.635mmol)をDMF(8mL)に溶解し、0℃に冷却した。その後、水素化ナトリウム(60% in oil)(76.3mg,1.91mmol)を加えた。反応溶液を25℃で20分間撹拌した後、2-フロイルクロリド(162μL,1.91mmol)を加えた。25℃で14時間撹拌した後、2N 水酸化ナトリウム水溶液を加え、ジエチルエーテルにより抽出した。有機層を2N 水酸化ナトリウム水溶液及び飽和食塩水で洗浄し、Na2SO4を加えて乾燥させ、濃縮した。粗生成物をシリカゲルカラムクロマトグラフィー(ヘキサン(1%トリエチルアミン)/酢酸エチル=1/1)により精製し、化合物5を白色粉末(収量:106mg;38%)として得た。化合物5の物性値は以下のとおりである。
Compound 4 (214.0 mg, 0.635 mmol) was dissolved in DMF (8 mL) and cooled to 0°C. Then sodium hydride (60% in oil) (76.3 mg, 1.91 mmol) was added. After the reaction solution was stirred at 25° C. for 20 minutes, 2-furoyl chloride (162 μL, 1.91 mmol) was added. After stirring at 25° C. for 14 hours, 2N aqueous sodium hydroxide solution was added and the mixture was extracted with diethyl ether. The organic layer was washed with 2N aqueous sodium hydroxide solution and saturated brine, dried by adding Na 2 SO 4 and concentrated. The crude product was purified by silica gel column chromatography (hexane (1% triethylamine)/ethyl acetate=1/1) to obtain compound 5 as a white powder (yield: 106 mg; 38%). The physical property values of compound 5 are as follows.
化合物5:
mp:94-95℃;
IR(ATR):1626cm-1(CO);
1H NMR(400MHz,CDCl3):δ=7.34(d,J=1.6Hz,1H),7.31(t,J=7.1Hz,1H),7.26(m,2H),7.19(m,4H),7.12(d,J=7.1Hz,1H),6.14(dd,J=3.0,1.6Hz,1H),5.30(d,J=3.0Hz,1H),4.23(tt,J=11.9,3.7Hz,1H),3.02(m,3H),2.76(m,2H),2.57(m,2H),2.24(s,3H),2.17(tdd,J=12.4,5.0,2.7Hz,2H),2.05(m,2H),1.65(m,2H),1.25(d,J=6.9Hz,3H),0.82(d,J=6.9Hz,3H);
13C NMR(100MHz,CDCl3):δ=159.7,148.3,147.4,144.3,140.4,137.7,137.1,129.0,128.7,128.4,128.3,126.0,124.9,115.1,111.0,60.3,57.6,53.3,53.2,33.7,29.9,28.2,24.5,24.2,19.3;several signals overlap;
HRMS(ESI):m/z calcd for C28H35N2O2:431.2693(M+H)+,found:431.2695. Compound 5:
mp: 94-95°C;
IR (ATR): 1626 cm −1 (CO);
1 H NMR (400 MHz, CDCl 3 ): δ = 7.34 (d, J = 1.6 Hz, 1 H), 7.31 (t, J = 7.1 Hz, 1 H), 7.26 (m, 2 H) , 7.19(m, 4H), 7.12(d, J=7.1Hz, 1H), 6.14(dd, J=3.0, 1.6Hz, 1H), 5.30(d, J = 3.0 Hz, 1H), 4.23 (tt, J = 11.9, 3.7 Hz, 1H), 3.02 (m, 3H), 2.76 (m, 2H), 2.57 ( m, 2H), 2.24 (s, 3H), 2.17 (tdd, J = 12.4, 5.0, 2.7Hz, 2H), 2.05 (m, 2H), 1.65 ( m, 2H), 1.25 (d, J = 6.9Hz, 3H), 0.82 (d, J = 6.9Hz, 3H);
13 C NMR (100 MHz, CDCl 3 ): δ=159.7, 148.3, 147.4, 144.3, 140.4, 137.7, 137.1, 129.0, 128.7, 128. 4, 128.3, 126.0, 124.9, 115.1, 111.0, 60.3, 57.6, 53.3, 53.2, 33.7, 29.9, 28.2, 24.5, 24.2, 19.3; several signals overlap;
HRMS ( ESI): m/z calcd for C28H35N2O2 : 431.2693 (M+H) < + > , found: 431.2695.
mp:94-95℃;
IR(ATR):1626cm-1(CO);
1H NMR(400MHz,CDCl3):δ=7.34(d,J=1.6Hz,1H),7.31(t,J=7.1Hz,1H),7.26(m,2H),7.19(m,4H),7.12(d,J=7.1Hz,1H),6.14(dd,J=3.0,1.6Hz,1H),5.30(d,J=3.0Hz,1H),4.23(tt,J=11.9,3.7Hz,1H),3.02(m,3H),2.76(m,2H),2.57(m,2H),2.24(s,3H),2.17(tdd,J=12.4,5.0,2.7Hz,2H),2.05(m,2H),1.65(m,2H),1.25(d,J=6.9Hz,3H),0.82(d,J=6.9Hz,3H);
13C NMR(100MHz,CDCl3):δ=159.7,148.3,147.4,144.3,140.4,137.7,137.1,129.0,128.7,128.4,128.3,126.0,124.9,115.1,111.0,60.3,57.6,53.3,53.2,33.7,29.9,28.2,24.5,24.2,19.3;several signals overlap;
HRMS(ESI):m/z calcd for C28H35N2O2:431.2693(M+H)+,found:431.2695. Compound 5:
mp: 94-95°C;
IR (ATR): 1626 cm −1 (CO);
1 H NMR (400 MHz, CDCl 3 ): δ = 7.34 (d, J = 1.6 Hz, 1 H), 7.31 (t, J = 7.1 Hz, 1 H), 7.26 (m, 2 H) , 7.19(m, 4H), 7.12(d, J=7.1Hz, 1H), 6.14(dd, J=3.0, 1.6Hz, 1H), 5.30(d, J = 3.0 Hz, 1H), 4.23 (tt, J = 11.9, 3.7 Hz, 1H), 3.02 (m, 3H), 2.76 (m, 2H), 2.57 ( m, 2H), 2.24 (s, 3H), 2.17 (tdd, J = 12.4, 5.0, 2.7Hz, 2H), 2.05 (m, 2H), 1.65 ( m, 2H), 1.25 (d, J = 6.9Hz, 3H), 0.82 (d, J = 6.9Hz, 3H);
13 C NMR (100 MHz, CDCl 3 ): δ=159.7, 148.3, 147.4, 144.3, 140.4, 137.7, 137.1, 129.0, 128.7, 128. 4, 128.3, 126.0, 124.9, 115.1, 111.0, 60.3, 57.6, 53.3, 53.2, 33.7, 29.9, 28.2, 24.5, 24.2, 19.3; several signals overlap;
HRMS ( ESI): m/z calcd for C28H35N2O2 : 431.2693 (M+H) < + > , found: 431.2695.
(工程3:化合物5の光学分割)
化合物5はラセミ体であるため、キラル高速液体クロマトグラフィー(HPLC)により、各アトロプ異性体を分離及び単離した。HPLCの分離条件は以下のとおりである。
-HPLC条件-
カラム:CHIRALPAK IG(Φ=4.6mm)
移動相:30%エタノール/ヘキサン
流速:0.5mL/分
温度:25℃
溶出時間:22.7分、37.7分 (Step 3: Optical resolution of compound 5)
Since compound 5 is racemic, each atropisomer was separated and isolated by chiral high performance liquid chromatography (HPLC). The HPLC separation conditions are as follows.
- HPLC conditions -
Column: CHIRALPAK IG (Φ=4.6mm)
Mobile phase: 30% ethanol/hexane Flow rate: 0.5 mL/min Temperature: 25°C
Elution time: 22.7 minutes, 37.7 minutes
化合物5はラセミ体であるため、キラル高速液体クロマトグラフィー(HPLC)により、各アトロプ異性体を分離及び単離した。HPLCの分離条件は以下のとおりである。
-HPLC条件-
カラム:CHIRALPAK IG(Φ=4.6mm)
移動相:30%エタノール/ヘキサン
流速:0.5mL/分
温度:25℃
溶出時間:22.7分、37.7分 (Step 3: Optical resolution of compound 5)
Since compound 5 is racemic, each atropisomer was separated and isolated by chiral high performance liquid chromatography (HPLC). The HPLC separation conditions are as follows.
- HPLC conditions -
Column: CHIRALPAK IG (Φ=4.6mm)
Mobile phase: 30% ethanol/hexane Flow rate: 0.5 mL/min Temperature: 25°C
Elution time: 22.7 minutes, 37.7 minutes
キラルHPLCにより分離及び単離された一対のアトロプ異性体のうち、溶出時間が早いアトロプ異性体を化合物5Fと表記し、溶出時間が遅いアトロプ異性体を化合物5Lと表記する。化合物5F及び化合物5Lの鏡像体過剰率は99.9%eeであった。また、化合物5Fと化合物5Lとの間の活性化自由エネルギー値ΔG‡は130.6kJ/mol(80℃,トルエン)であった。化合物5F及び化合物5Lの比旋光度は以下のとおりである。
[α]D 20(5F):+44.483°(c=1.00,MeOH)
[α]D 20(5L):-46.175°(c=1.00,MeOH) Of the pair of atropisomers separated and isolated by chiral HPLC, the atropisomer with a faster elution time is designated ascompound 5F, and the atropisomer with a later elution time is designated as compound 5L. The enantiomeric excess of compound 5F and compound 5L was 99.9% ee. Also, the activation free energy value ΔG ‡ between compound 5F and compound 5L was 130.6 kJ/mol (80° C., toluene). The specific rotations of compound 5F and compound 5L are as follows.
[α] D 20 (5F): +44.483° (c=1.00, MeOH)
[α] D 20 (5 L): −46.175° (c=1.00, MeOH)
[α]D 20(5F):+44.483°(c=1.00,MeOH)
[α]D 20(5L):-46.175°(c=1.00,MeOH) Of the pair of atropisomers separated and isolated by chiral HPLC, the atropisomer with a faster elution time is designated as
[α] D 20 (5F): +44.483° (c=1.00, MeOH)
[α] D 20 (5 L): −46.175° (c=1.00, MeOH)
<試験例3:化合物5F及び化合物5Lのin vitroにおけるオピオイドμ受容体作用及びオピオイドμ受容体拮抗作用の評価>
オピオイドμ受容体発現細胞(CHO-μ細胞)を10% FBS含有nutrient mixture/Ham’s F-12培地に懸濁し、5.0×104細胞/ウェルとなるように96ウェルプレートに播種し、37℃、5.0% CO2の条件下にて培養した。24時間後、培地を100μL/ウェルのComponent B(HBSS+20mM HEPESバッファー、pH7.4)に置換し、カルシウム感受性蛍光指示薬(FLIPR Calcium 4 Assay kit、Molecular Devices社)を用いて、薬物刺激による細胞内Ca2+応答を測定した。具体的に、オピオイド受容体作用については、化合物5F又は化合物5Lを添加した後、2秒ごとに90秒間に亘って蛍光値を測定した。また、オピオイド受容体拮抗作用については、化合物5F又はオピオイドμ受容体拮抗薬であるナロキソンを添加し、装置内に30分間静置した後、オピオイドμ受容体作用薬であるフェンタニル(0.025μM)を添加し、同様に蛍光値を測定した。蛍光測定にはFlexstation 3(Molecular Devices社)を使用し、測定条件は励起波長485nm、蛍光波長525nm、カットオフ波長515nmとした。データの解析には、SOFTMAX PROソフトウェア(Molecular Devices社)を使用した。 <Test Example 3: Evaluation of in vitro opioid μ receptor activity and opioid μ receptor antagonistic activity ofcompound 5F and compound 5L>
Opioid μ receptor-expressing cells (CHO-μ cells) were suspended in a nutritive mixture/Ham's F-12 medium containing 10% FBS, and seeded in a 96-well plate at 5.0×10 4 cells/well. , 37° C., 5.0% CO 2 . After 24 hours, the medium was replaced with 100 µL/well of Component B (HBSS + 20 mM HEPES buffer, pH 7.4), and a calcium-sensitive fluorescent indicator (FLIPR Calcium 4 Assay kit, Molecular Devices) was used to measure intracellular Ca by drug stimulation. 2+ responses were measured. Specifically, for opioid receptor activity, fluorescence values were measured every 2 seconds for 90 seconds after addition of compound 5F or compound 5L. Further, for opioid receptor antagonism, compound 5F or naloxone, which is an opioid μ receptor antagonist, was added and allowed to stand in the device for 30 minutes. was added, and the fluorescence value was measured in the same manner. Flexstation 3 (Molecular Devices) was used for fluorescence measurement, and the measurement conditions were an excitation wavelength of 485 nm, a fluorescence wavelength of 525 nm, and a cutoff wavelength of 515 nm. SOFTMAX PRO software (Molecular Devices) was used for data analysis.
オピオイドμ受容体発現細胞(CHO-μ細胞)を10% FBS含有nutrient mixture/Ham’s F-12培地に懸濁し、5.0×104細胞/ウェルとなるように96ウェルプレートに播種し、37℃、5.0% CO2の条件下にて培養した。24時間後、培地を100μL/ウェルのComponent B(HBSS+20mM HEPESバッファー、pH7.4)に置換し、カルシウム感受性蛍光指示薬(FLIPR Calcium 4 Assay kit、Molecular Devices社)を用いて、薬物刺激による細胞内Ca2+応答を測定した。具体的に、オピオイド受容体作用については、化合物5F又は化合物5Lを添加した後、2秒ごとに90秒間に亘って蛍光値を測定した。また、オピオイド受容体拮抗作用については、化合物5F又はオピオイドμ受容体拮抗薬であるナロキソンを添加し、装置内に30分間静置した後、オピオイドμ受容体作用薬であるフェンタニル(0.025μM)を添加し、同様に蛍光値を測定した。蛍光測定にはFlexstation 3(Molecular Devices社)を使用し、測定条件は励起波長485nm、蛍光波長525nm、カットオフ波長515nmとした。データの解析には、SOFTMAX PROソフトウェア(Molecular Devices社)を使用した。 <Test Example 3: Evaluation of in vitro opioid μ receptor activity and opioid μ receptor antagonistic activity of
Opioid μ receptor-expressing cells (CHO-μ cells) were suspended in a nutritive mixture/Ham's F-12 medium containing 10% FBS, and seeded in a 96-well plate at 5.0×10 4 cells/well. , 37° C., 5.0% CO 2 . After 24 hours, the medium was replaced with 100 µL/well of Component B (HBSS + 20 mM HEPES buffer, pH 7.4), and a calcium-sensitive fluorescent indicator (
化合物5F(5F)又は化合物5L(5L)を添加したときの用量反応曲線を図4に示す。図4から分かるように、化合物5Lを添加した場合には、濃度依存的に蛍光値の増加が確認されたが、50%効果濃度(EC50値)は6.72×10-9Mであり、試験例1のフェンタニルよりも弱かった。一方、化合物5Fを添加した場合には、蛍光値の増加は確認されなかった。
Dose-response curves for the addition of compound 5F (5F) or compound 5L (5L) are shown in FIG. As can be seen from FIG. 4, when compound 5L was added, a concentration-dependent increase in fluorescence value was confirmed, but the 50% effective concentration ( EC50 value) was 6.72×10 −9 M. , was weaker than fentanyl in Test Example 1. On the other hand, when compound 5F was added, no increase in fluorescence value was confirmed.
また、化合物5F(5F)又はナロキソン(NLX)で前処理した後、フェンタニルを添加したときの用量反応曲線を図5に示す。図5から分かるように、フェンタニルの効果は化合物5F及びナロキソンにより濃度依存的に抑制された。50%阻害濃度(IC50値)は、化合物5Fが2.61×10-6M、ナロキソンが1.84×10-7Mであり、化合物5Fの方がナロキソンよりも弱いものの、いずれも強力なオピオイドμ受容体拮抗作用を有していた。
Also shown in FIG. 5 is the dose-response curve when fentanyl was added after pretreatment with compound 5F (5F) or naloxone (NLX). As can be seen from FIG. 5, the effect of fentanyl was suppressed by compound 5F and naloxone in a dose-dependent manner. The 50% inhibitory concentration (IC 50 value) was 2.61×10 −6 M for compound 5F and 1.84×10 −7 M for naloxone. Although compound 5F was weaker than naloxone, both were potent. had significant opioid μ-receptor antagonism.
Claims (8)
- 下記式(1)で表される化合物が有する一対のアトロプ異性体のうち、オピオイド受容体拮抗作用を有する一方のアトロプ異性体又はその薬理学的に許容される塩を有効成分として含有するオピオイド受容体拮抗剤。
- 前記式(1)中のR1がヘテロアリール基であり、R2及びR3がそれぞれ独立にアルキル基である、請求項1に記載のオピオイド受容体拮抗剤。 The opioid receptor antagonist according to Claim 1, wherein R1 in said formula (1) is a heteroaryl group, and R2 and R3 are each independently an alkyl group.
- オピオイドμ受容体に対して拮抗作用を示す、請求項1又は2に記載のオピオイド受容体拮抗剤。 The opioid receptor antagonist according to claim 1 or 2, which exhibits an antagonistic effect on opioid μ receptors.
- 下記式(2)で表され、且つ、クロロホルムに溶解したときのナトリウムD線に対する20℃における比旋光度が正の値を示すアトロプ異性体を前記有効成分として含有する、請求項1~3のいずれか1項に記載のオピオイド受容体拮抗剤。
- 下記式(3)で表され、且つ、メタノールに溶解したときのナトリウムD線に対する20℃における比旋光度が正の値を示すアトロプ異性体を前記有効成分として含有する、請求項1~3のいずれか1項に記載のオピオイド受容体拮抗剤。
- 下記式(1)で表される化合物が有する一対のアトロプ異性体のうち、オピオイド受容体拮抗作用を有する一方のアトロプ異性体又はその薬理学的に許容される塩を有効成分として含有する医薬組成物。
- 下記式(2)で表され、且つ、クロロホルムに溶解したときのナトリウムD線に対する20℃における比旋光度が正の値を示す化合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023551319A JPWO2023054006A1 (en) | 2021-09-28 | 2022-09-16 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-158379 | 2021-09-28 | ||
JP2021158379 | 2021-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023054006A1 true WO2023054006A1 (en) | 2023-04-06 |
Family
ID=85782503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/034681 WO2023054006A1 (en) | 2021-09-28 | 2022-09-16 | Opioid receptor antagonist and pharmaceutical composition |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2023054006A1 (en) |
WO (1) | WO2023054006A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60248670A (en) * | 1984-04-09 | 1985-12-09 | ビ−オ−シ− インコ−ポレ−テツド | N-aryl-n-(4-piperidinyl)amide, drug, composition and method |
WO2006101245A1 (en) * | 2005-03-23 | 2006-09-28 | Nippon Chemiphar Co., Ltd. | N-substituted-n-(4-piperidinyl) amide derivative |
US20210396706A1 (en) * | 2020-06-22 | 2021-12-23 | The Florida International University Board Of Trustees | Aptamer-based sensors for detection of fentanyl opioids |
-
2022
- 2022-09-16 JP JP2023551319A patent/JPWO2023054006A1/ja active Pending
- 2022-09-16 WO PCT/JP2022/034681 patent/WO2023054006A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60248670A (en) * | 1984-04-09 | 1985-12-09 | ビ−オ−シ− インコ−ポレ−テツド | N-aryl-n-(4-piperidinyl)amide, drug, composition and method |
WO2006101245A1 (en) * | 2005-03-23 | 2006-09-28 | Nippon Chemiphar Co., Ltd. | N-substituted-n-(4-piperidinyl) amide derivative |
US20210396706A1 (en) * | 2020-06-22 | 2021-12-23 | The Florida International University Board Of Trustees | Aptamer-based sensors for detection of fentanyl opioids |
Non-Patent Citations (4)
Title |
---|
DUFFY JONATHAN, URBAS AARON, NIEMITZ MATTHIAS, LIPPA KATRICE, MARGINEAN IOAN: "Differentiation of fentanyl analogues by low-field NMR spectroscopy", ANALYTICA CHIMICA ACTA, vol. 1049, 1 February 2019 (2019-02-01), AMSTERDAM, NL , pages 161 - 169, XP093054470, ISSN: 0003-2670, DOI: 10.1016/j.aca.2018.12.014 * |
LAMY FRANCOIS R.; DANIULAITYTE RAMINTA; BARRATT MONICA J.; LOKALA USHA; SHETH AMIT; CARLSON ROBERT G.: "Listed for sale: Analyzing data on fentanyl, fentanyl analogs and other novel synthetic opioids on one cryptomarket", DRUG AND ALCOHOL DEPENDENCE, vol. 213, 12 June 2020 (2020-06-12), IR , XP086215752, ISSN: 0376-8716, DOI: 10.1016/j.drugalcdep.2020.108115 * |
LURIE, I.S. ; IIO, R.: "Use of multiple-reaction monitoring ratios for identifying incompletely resolved fentanyl homologs and analogs via ultra-high-pressure liquid chromatography-tandem mass spectrometry", JOURNAL OF CHROMATOGRAPHY A, vol. 1216, no. 9, 27 February 2009 (2009-02-27), AMSTERDAM, NL, pages 1515 - 1519, XP025909474, ISSN: 0021-9673, DOI: 10.1016/j.chroma.2008.12.097 * |
SINGH P., PAI U. B.: "EFFECT OF MOLECULAR SIZE ON OPIATE RECEPTOR AFFINITY OF FENTANYL DERIVATIVES & ALPHA1-AGONIST POTENCY OF 2-AMINOTETRALINS.", INDIAN JOURNAL OF CHEMISTRY, COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (C S I R), IN, vol. 22B., no. 10., 1 October 1983 (1983-10-01), IN , pages 1076 - 1078., XP000853930, ISSN: 0019-5103 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2023054006A1 (en) | 2023-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102459202B (en) | As the inhibitor isoxazoline of fatty acid amide hydrolase | |
EP3703680B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
AU2018257203B2 (en) | Novel tetrahydronaphthyl urea derivatives | |
ES2899694T3 (en) | Novel compounds, their synthesis and their uses | |
CN103068384A (en) | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites | |
EP3665175B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
EP3697781B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
CA3068842A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
WO2022129909A1 (en) | Cannabinoid derivatives as pharmaceutically active compounds and method of preparation thereof | |
FR2593818A1 (en) | ACYLAMINOMETHYL-3 IMIDAZO (1,2-A) PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | |
WO2023054006A1 (en) | Opioid receptor antagonist and pharmaceutical composition | |
CA3217661A1 (en) | Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof | |
CN118076354A (en) | Methods of treating migraine with MNK inhibitors | |
CN112574212B (en) | Pyrimido five-membered nitrogen heterocyclic derivative, preparation method and medical application thereof | |
WO2022125614A1 (en) | Phosphonates as inhibitors of enpp1 and cdnp | |
CA3012839A1 (en) | Tetrahydroisoquinoline derivatives | |
KR20230041715A (en) | Pyridine-1,5-diones exhibiting MNK inhibition and methods of use thereof | |
CA3178647A1 (en) | Substituted tricyclic amides, analogues thereof, and methods using same | |
CN116963733A (en) | Imidazole compounds as ENPP1 inhibitors | |
WO2022164842A1 (en) | Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5 | |
EP4262980A1 (en) | Cannabinoid derivatives as pharmaceutically active compounds and method of preparation thereof | |
CN116600813A (en) | Phosphonates as ENPP1 and CDNP inhibitors | |
EP3369736A1 (en) | Morphinan derivative and medical usage thereof | |
CN115703767A (en) | Preparation method of 3-aryloxy-3-five-membered heteroaryl-propylamine compound | |
CN116496270A (en) | 4-aminopiperidine derivative and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22875877 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023551319 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |